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B cells express toll-like receptor 9 (TLR9), that recognizes microbial DNA 
containing unmethylated cytosyl guanosyl (CpG) sequences, induces innate immune 
responses and facilitates antigen-specific adaptive immunity.  Studies indicate that in 
addition to stimulating innate immunity, TLR9 ligands can induce apoptosis in TLR9 
expressing cancer cells.  To understand the mechanism for TLR9-induced apoptosis, we 
compared the effects of CpG containing oligodeoxynucleotides (CpG ODN) on mouse 
primary, splenic B cells and a mouse lymphoma B cell line, CH27. CpG ODN stimulated 
the proliferation of primary B cells but inhibited cell proliferation and induced apoptosis 
in CH27 lymphoma B cells in a sequence-specific, TLR9-dependent fashion. While CpG 
ODN induced sustained activation of NF-κB and increase in c-myc protein levels in 
primary B cells, NF-κB activation was transient in the lymphoma B cells. These data 
suggest that the differential effects of CpG DNA on primary and lymphoma B cells occur 
due to differences in NF-κB activation.  The CpG ODN-induced impaired NF-κB 
activation in the lymphoma B cells results in an imbalance between NF-κB and c-myc 
activities, inducing apoptosis in TLR9-expressing B lymphoma cells. 
The B cell antigen receptor (BCR) binds to antigens in their native form. The 
BCR can distinguish subtle differences in antigen structure and trigger differential 
responses.  Here, we analyzed the effects of antigen valency on the functions of the BCR 
using three different antigen systems – anti-BCR antibody –based antigens, 
phosphorylcholine (PC)-based antigens, and hen egg lysozyme (HEL)-based antigens.  
While both paucivalent and polyvalent antigens induced the redistribution of surface 
BCR into microdomains, polyvalent antigen-induced BCR microdomains persisted. 
Significantly, this trend was consistently observed in all three antigen systems studied. 
Ganglioside GM1, tyrosine-phosphorylated proteins and phosphorylated ERK colocalized 
with BCR microdomains, suggesting these function as surface signaling microdomains. 
Co-receptor, CD19 and MHC class II molecules, but not CD45 and transferrin receptor, 
concentrated in the BCR surface microdomains. Prolonged BCR caps were also 
concomitant with a reduction in BCR movement to late endosomes/lysosomes. Thus, 
antigen valency influences B cell responses by modulating the stability of BCR-signaling 
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Chapter 1: General Introduction  
The vertebrate immune system comprises the innate and adaptive immune systems. The 
innate immune system is an evolutionarily conserved, ancient mechanism of host defense, 
and is utilized by members of both the plant and animal kingdoms [1-4]. The innate 
immune response occurs upon recognition of highly conserved molecular structures 
present on invading microorganisms by the host cells. These structures, called pathogen-
associated molecular patterns (PAMPs) are recognized by pathogen recognition receptors 
(PRRs) expressed on host cells [5]. They are germline encoded, non-clonal receptors 
which rapidly activate effector cells. Leukocytes like macrophages, neutrophils, 
eosinophils, mast cells, dendritic cells, cells of the skin, and epithelia of the gut and lung 
express PRRs and are involved in initiating an innate immune response. The main 
functions of this response are phagocytosis and killing of microbes and activation of 
complement and pro-inflammatory pathways [6]. The adaptive immune system is a more 
recent evolutionary adaptation acquired only by the vertebrate phylum. The adaptive 
immune response is initiated by clonally distinct antigen receptors expressed by B and T 
lymphocytes. These antigen receptors are generated by random gene rearrangements and 
recognize specific features of a particular pathogen [7]. Activation of the B and T cells 
occurs later in the immune response and results in the generation of ‘memory’ cells, 
which allows for a stronger and quicker response on re-encountering the same microbe 
[5].  
 
Upon encountering a pathogen, the innate immune response is activated rapidly and 
provides the initial protection, following which it facilitates the activation of the adaptive 
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immune response. This leads to more effective clearance of the pathogen and generates 
memory cells against them. Hence, vertebrates which utilize both arms of the immune 
response have benefited tremendously in generating optimal host defense. 
 
1.1 B lymphocytes and BCR  
Among the lymphocytes involved in the adaptive immune response, the B cells are 
unique as they are the only cells that can differentiate into antibody-secreting cells and 
initiate a humoral immune response. Antibodies neutralize toxins from the invading 
microbe and opsonize microbes, targeting them to macrophages and complement 
pathways. The B cells arise from hematopoietic progenitors and differentiate in the bone 
marrow and migrate to the spleen as transitional B cells. In the spleen they transition 
from being newly emigrant T1 cells to T2 cells and then to mature B cells. The 
generation and maintenance of the T1 and T2 cells depends on signals from the B cell 
antigen receptor (BCR) and B-cell activating factor of the tumor-necrosis-factor family 
(BAFF) [8, 9]. Mature B cells are further classified as B1 B cells which reside in the 
pleural and peritoneal cavities and the conventional B2 B cells. B2 B cells include 
marginal zone B cells that are found in the marginal zone of the spleen and follicular B 
cells residing in the follicles of the lymph nodes and spleen [10]. It is hypothesized that 
activation of different BCR signaling components leads to the generation of different 
mature B cell subsets [11]. Mature, naïve, resting B cells express functional, clonally 




The B cell antigen receptor (BCR) comprises of a membrane immunoglobulin (mIg) 
covalently associated with Igα/Igβ heterodimer. The mIg is formed by somatic 
recombination of a limited number of gene segments. The germline Ig light chain locus 
has multiple copies of three types of gene segments - variable (V), joining (J) and 
constant (C). The heavy chain locus has an additional fourth segment called diversity (D) 
segment. The variable region of the heavy chain is formed by random recombination of 
one each of the V, D and J segments, along with one C region. The light chain is formed 
by recombination of V, J and C regions [12]. This process is coordinated by the V(D)J 
recombinase, which includes proteins encoded by recombination-activating gene 1 and 2 
(RAG1 and RAG2) and DNA-dependent protein kinase (DNA-PK). These proteins bind 
to specific recombination signal sequences (RSS) found adjacent to the V, D, and J 
segments and initiate V(D)J recombination [13]. V(D)J recombination generates heavy 
and light chains of varying specificities. Juxtaposing a recombined heavy with a 
recombined light chain increases the diversity of the functional antigen receptor. The 
diversity of the receptors is further enhanced by addition or deletion of non-template 
encoded, N-nucleotides or palindromic, P-nucleotides at the junctions between the V, D 
and J gene segments. The combination of these processes results in an astounding 
repertoire of antibodies with nearly 1011 distinct specificities [12].  
 
The B cell antigen receptor (BCR) comprises two components. The membrane 
immunoglobulin (mIg), also called surface Ig (sIg), is the ligand binding domain and the 
Igα/Igβ heterodimer is the signal transducing domain. The mIg is composed of two heavy 
chains and two light chains which have repeating immunoglobulin (Ig) domains. Each 
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heavy chain is linked to a light chain and to the other heavy chain by disulfide bonds. The 
heavy and light chains each have an N-terminal variable region and a C-terminal constant 
region. The variable regions of the heavy and light chains are exposed to the extracellular 
space and together form the antigen binding site. Mature resting B cells express mIgM 
and mIgD, whose heavy chains have very short cytoplasmic tails made of 3 amino acids.  
 
The Igα/Igβ heterodimer associates non-covalently with the mIg and this association is 
required for mIg expression [14]. Igα and Igβ are covalently linked by disulfide bonds 
and each spans the membrane once. Their cytoplasmic tails are 61 and 48 amino acids 
respectively, containing an immunoreceptor tyrosine-based activation motif (ITAM) in 
each chain [15]. The ITAM is a consensus motif that is involved in signal transduction 
and is found in the cytoplasmic tails of many signaling molecules including CD3 and ζ 
chains of the T cell antigen receptor (TCR) complex and several Fc receptors. 
Phosphorylated tyrosines of the ITAMs provide binding sites for proteins with a Src-2 
homology (SH2) domain and initiate signaling transduction. The individual roles of Igα 
and Igβ however, remain to be defined and it has been shown that they play different 
roles in signal transduction from the BCR [16, 17].  
 
It was postulated that each heavy chain of the mIg associates with an Igα/Igβ heterodimer 
as this would allow the Igα/Igβ to neutralize the polar amino acids in each of two 
transmembrane domain of the mIg. Schamel and Reth, using biochemical analyses 
showed that every mIg associates with only one Igα/Igβ heterodimer [18]. More recently, 
fluorescence resonance energy transfer (FRET) studies of live cells has confirmed the 1:1 
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stoichiometry of mIg and Igα/Igβ heterodimer [19], although the arrangement of the mIg 
and the Igα /Igβ heterodimer still remains unclear.  
 
The B cell is triggered by antigen binding to the BCR. The BCR performs two unique, 
yet interrelated functions. The first is to initiate and transmit signals and the second is to 
internalize the antigen and process it for presentation to T cells on major 
histocompatibility complex class II (MHC II) molecules. These two events provide the 
two stages of signals for B cell activation.  
 
1.2 BCR signaling 
The BCR complex has no intrinsic tyrosine kinase activity. It relies on a set of protein 
tyrosine kinases (PTKs) that belong to the Src, Syk and Tec families for signaling. 
Binding of multivalent antigens to the BCR leads to clustering of surface BCRs and 
association of the clustered receptors with lipid rafts (Fig. 1-1). Lipid rafts are regions of 
the membrane that are rich in cholesterol and glycosphingolipids and are detergent 
insoluble [20]. Lipid rafts provide a platform for signaling and serve to include or 
exclude proteins [21]. For example, in the resting, mature B cell the monomeric BCR is 
excluded from the rafts while the Src kinase Lyn is constitutively present in lipid rafts 
[20]. Oligomeric BCR clusters that move into the rafts associate almost exclusively with 
Lyn [22], which phosphorylates the ITAMs of Igα/Igβ. The Src kinases Fyn and Blk are 
also implicated in this role. Fyn and Blk are thought to be redundant to Lyn, as loss of 
either does not have significant impact on BCR signaling [23]. Recent evidence from 
fluorescence resonance energy transfer (FRET) studies suggests that receptor engagement  
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Figure 1-1. BCR signaling pathway. 
Upon antigen binding the BCR translocates to lipid rafts from where it initiates the 
signaling cascade. Shown is a simplified schematic of the BCR signaling pathway. (A) 
Upon antigen binding, Src kinase, Lyn phosphorylates the ITAMs of Igα/Igβ and Syk 
tyrosine kinase. (B) Syk recruits and activates the adaptor protein, BLNK, PI-3Kinase 
and Btk. (C) BLNK provides docking sites for various proteins which amplify the 
antigen-induced signaling. BCR signaling culminates in the activation of transcription 
factors like NF-κB, AP-1, and ATF-2, which control gene expression.  (D) In addition, 
accessory molecules like CD19/CD21 co-receptor complex enhance signaling by 



























































































































leads to a conformational change of the Igα/Igβ heterodimer of the BCR from a ‘closed’ 
to an ‘open’ form which facilitates phosphorylation of the ITAMs by Src-family kinases 
[19]. The phosphorylated ITAMs amplify the signal by recruiting Syk tyrosine kinase 
[24]. Syk is activated by the Src kinases and by autophosphorylation [25]. Syk is a crucial 
player in BCR signaling as disruption of Syk impairs most downstream signaling events 
[26]. The adaptor protein, B cell linker (BLNK) also called SLP-65 is activated by Syk 
and provides docking sites for various proteins like Bruton’s tyrosine kinase (Btk), 
phospholipase C-γ 2 (PLC-γ2), and adaptor proteins, Grb-2, Vav and Nck [27]. Hence 
BLNK is a central element in BCR signaling and BLNK-deficient mice show severe 
defects in BCR signaling, similar to Syk [28]. Recruitment of Btk to the proximity of Syk 
by BLNK makes it a target for Syk and Lyn phosphorylation and increases its activity 
[29]. Btk in turn phosphorylates and activates (PLC-γ2). In addition to BLNK, Syk also 
activates phosphoinositide -3- kinase (PI3K) and the Ras-Raf-ERK pathways [30, 31]. 
Hence, antigen binding to the BCR leads to a sequential activation of Lyn, Syk and Btk 
which amplifies the signal and initiates a number of downstream pathways.  
 
CD19 that associates with complement receptor CD21, is phosphorylated by Lyn upon 
BCR engagement by antigen and provides binding sites for Vav, Rac and PI3K [32]. Rac 
along with Syk activates PI3K. Both PI3K and PLC- γ2 use phosphatidyl inositol 4,5 – 
bisphosphate (PIP2) as their substrate. PI3K phosphorylates PIP2 to phosphatidyl inositol 
1,4,5 – trisphosphate (PIP3) which recruits molecules with pleckstrin homology (PH) 
domains, like Btk, to the BCR signalosome. PI3K also activates Akt, a serine-threonine 
kinase, which promotes proliferation by inhibiting BAD, a pro-apoptotic protein. PLC- γ2  
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 hydrolyzes PIP2 to inositol trisphosphate (InsP3) and diacyl glycerol (DAG), which 
releases intracellular calcium and activates protein kinase C β (PKC-β). PKC-β activates 
nuclear factor-κB (NF-κB), which upregulates the anti-apoptotic protein Bcl-xl and 
cyclin D2 [33]. PKC-β and Rac activate mitogen activated protein kinases (MAPKs) – 
p38, c-Jun NH2 terminal kinase (JNK), and extracellular signal regulated kinase (ERK) 
[34]. The MAP kinases activate specific transcription factors, like c-jun, c-fos, Elk and c-
Myc which along with NF-κB and NFAT impact the cellular response to antigen 
engagement [35].  
 
BCR signaling is influenced by receptor-associated accessory molecules. CD19/CD21 
complex enhances signaling by the BCR by recruiting and activating Lyn, PI-3k and Vav 
[32], and is essential for B cell response to thymus-dependent protein antigens [36]. 
CD22, the paired immunoglobulin-like receptor B (PIRB) and FcγRIIB are negative 
regulators of BCR signaling. These molecules have immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) in their cytoplasmic tails. They recruit phosphatases Src-
homology-2 (SH2)-domain-containing inositol 5-phosphatase (SHIP) and (SH2)-domain-
containing protein tyrosine phosphatase 1 (SHP1) which serve to down regulate and 
inhibit BCR signaling [37, 38]. Interestingly these negative regulators, like CD22 and 
SHP1, are excluded from the lipid rafts [20].  
 
A model of BCR signaling has started to emerge where the BCR is thought to actively 
assemble a signaling complex or ‘signalosome’ in the lipid raft where it is protected from 
negative regulators like phosphatases. Thus the B cell receptor uses a number of effector 
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enzymes, adaptor proteins and the lateral heterogeneities of the plasma membrane to 
regulate the precision of its signal transduction and influence cell fate decisions.  
 
1.3 Cellular responses of B cells 
Humoral immune responses are initiated by antigen binding to the B cell antigen receptor. 
The developmental stage of the B cells, the nature of the antigenic stimulus and the 
availability of T cell-dependent and independent stimuli control the cellular response of B 
cells. Splenic marginal zone (MZ) B cells and peritoneal B1 B cells are the first 
responders which sense T-cell independent antigens like bacterial polysaccharide. 
Follicular B cells respond to protein antigens and require the help of antigen-specific 
CD4+ T cells. T-dependent responses lead to the formation of memory B cells, a hallmark 
of adaptive immunity. In both cases activation of B lymphocytes is a multi-step process 
where many external signals are integrated to result in a cellular response. 
 
1.3.1 Thymus-Independent (TI) antigens 
There are two types of thymus-independent (TI) antigens. Type 1 TI antigens like 
bacterial lipopolysaccharide (LPS) and peptidoglycan are polyclonal B cell activators 
which are Toll-like receptor (TLR) ligands and induce non-antigen specific B cell 
responses. Type 2 TI (TI-2) antigens induce antigen-specific B cell activation [39]. TI-2 
antigens are characterized by large molecular weight and multiple repeating antigenic 
epitopes that mediate extensive cross-linking of BCR. Antigens like polysaccharides and 
lipids present on the surface of capsulated bacteria, the cell wall of non-encapsulated 
bacteria and viral capsids are TI-2 antigens [40]. TI-2 antigens, like phosphorylcholine 
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expressed on bacterial cell walls effectively activate MZ and B1 B cells and induce 
proliferation, Ig secretion and plasma cell differentiation [41]. It has been suggested that 
TI-2 antigen induced Ig secretion requires a second signal from T-independent sources. 
B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) expressed 
on macrophages, monocytes and dendritic cells have been implicated in this role. They 
bind to transmembrane activator and CAML interactor (TACI) and B cell maturation 
antigen (BCMA) on B cells and modulate survival and activation [42, 43], and are 
essential for B cell response to TI antigens [42]. TACI-deficient mice do not respond to 
TI-2 antigens [44]. Microbial products like LPS, bacterial lipoproteins and bacterial DNA 
containing the unmethylated CpG dinucleotide motif activate the Toll-like receptor 
(TLR) pathway and synergize with TI-2 antigens to enhance B cell proliferation and Ig 
secretion [45-47], potentially providing a second signal for TI-2 antigen-triggered B cell 
activation. Furthermore, TI-2 antigens can activate the complement pathway, which 
lowers the threshold of antigen needed for B cell proliferation [48] and BCR signaling 
threshold through CD19/CD21 co-receptor. B cells exposed to TI antigens undergo 
proliferation, class switching and can form germinal centers. This is exemplified by the 
formation of germinal centers (GCs) when mice lacking CD3+ T cells are immunized 
with NP-Ficoll, a prototypical TI-2 antigen [49]. However, these GCs are short-lived and 
the cells do not undergo somatic hypermutation to differentiate into memory B cells. 
Thus TI-2 antigens activate the host to rapidly produce antibodies with help from non-T 
cell sources, which prevents the multiplication and spreading of invading microbes in the 




1.3.2 Thymus-dependent (TD) antigens 
B cells typically detect soluble antigens but they can also interact with native antigens 
that are presented by antigen presenting cells like follicular dendritic cells. B cells that 
recognize membrane-bound antigen spread over these antigen presenting cells and then 
contract to accumulate and extract the antigen [50]. Naïve B cells which form an immune 
synapse with antigen presenting dendritic cells rearrange their BCRs to form a central 
ring and excluding negative co-receptors like CD45 and CD22 [51]. Adhesion molecules 
like ICAM-1 and VCAM-1 on the antigen-tethered cells interact with LFA-1 and VLA-4 
on the B cells, creating a docking site for the B cells on the target cells [52, 53]. This 
could reduce the threshold of B cell activation since the formation of such synapses could 
be more potent in activating the B cells.  
 
T-dependent (TD) responses require the recognition of antigen by cognate B and T 
lymphocytes. Lanzavecchia showed that this occurs by the recognition of native antigen 
by BCR and processed antigen by TCR in the context of MHC class II [54]. Real time 
imaging analysis of mice injected with hen egg lysozyme (HEL) antigen shows that the 
antigen experienced B cells migrate to the B cell-T cell boundary of the lymph nodes [55],  
where antigen activated T and B cells sample each other and establish interaction with 
cells of cognate antigen specificity. The B-T conjugate lasts for about 20-40 min [55]. An 
extensive and active rearrangement of the surface molecules takes place in both cells 
forming the immune synapse. The TCR which recognizes cognate MHC class II and 
kinases like ZAP70 and Lck, migrate to the centre of a ring surrounded by molecules 
involved in cell adhesion like LFA-1 and talin [56, 57]. This structure is called a supra 
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molecular activation cluster (SMAC) [58]. The TCR forms microclusters within 30 
seconds of stimulation and initiates signaling, before merging together as the central 
SMAC or cSMAC [59]. Upon formation of the cSMAC the TCRs stop signaling and are 
sorted for degradation [60].  
 
Importantly upon B-T conjugate formation, cytokines secreted by T cells and signaling 
triggered by the interaction of co-stimulatory molecules on both cells activate B cells to 
undergo clonal expansion and differentiation into antibody-secreting cells. CD40 which 
is constitutively expressed on B cells binds CD154 or CD40 ligand (CD40L) on activated 
T cells and is essential for class switching and GC formation [61, 62]. Class switching 
refers to the process of isotype switching of the heavy chain from μ and δ to γ, α and ε. 
This occurs by a mechanism called class switch recombination (CSR). During this 
process the rearranged VDJ gene segment of the heavy chain recombines with 
downstream γ, α or ε C regions leading to production of IgG, IgA or IgE antibodies. 
Inducible costimulator (ICOS) present on T cells binds its ligand (ICOSL) on B cells and 
acts upstream of CD40 [63]. ICOS-deficient mice do not undergo CSR or GC formation 
[64]. ICOS belongs to the B7-CD28 family. Members of this family, including B7.1 and 
B7.2 on B cells and CD28 on T cells, are upregulated sequentially. While they are crucial 
in the immunologic synapses between DCs and T cells, their importance in the 
immunological synapses between B and T cells is unclear [65]. OX40-OX40L and 
CD27-CD70 interactions have also been implicated in the co-stimulation provided by B-
T cell interaction [54]. Activated CD4+ T cells secrete cytokines that along with co-
stimulatory molecules stimulate B cell proliferation and differentiation. Cytokines are 
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soluble proteins that mediate effector functions of cells. Activated CD4+ T cells secrete 
IL-2, IL-4 and IL-5 to promote B cell proliferation and isotype switching. IL-6 is 
important for growth of IgM-secreting plasma B cells. CD40 ligand and cytokines 
secreted by CD4+T cells activate B cell proliferation and Ig secretion.  
 
Upon stimulation by cognate T cells, the B cells undergo clonal expansion and 
differentiate into short-lived plasma cells or enter the lymphoid follicle to form germinal 
centers (GCs). The short-lived plasma cells secrete germ-line encoded antigen-specific 
antibodies [66]. The B cells that enter the lymphoid follicle form a germinal center where 
they rapidly proliferate and diversify their BCR through somatic hypermutation (SHM) 
[67]. During SHM, the VDJ segments of Ig heavy chain and VJ segments of Ig light 
chain typically undergo base substitution or small deletions. The BCRs accumulate one 
mutation with each cell division. B cells expressing BCRs with higher affinity are 
positively selected by cognate T cells in the germinal center [68]. Hence this process is 
also called affinity maturation. Upon exiting the GC they differentiate to form long-lived 
memory B cells or long-lived plasma cells. The long-lived plasma cells home to the bone 
marrow and secrete high affinity antibodies, which serves to maintain antibody levels for 
the life of the animal. The affinity-matured memory B cells are non-secreting cells that 
circulate or home to the marginal zone of the spleen and rapidly proliferate and 
differentiate to plasma cells upon antigen reencounter [69]. Thus B cells reacting to T-
dependent antigens give rise to antibodies and memory cells which are considered 




Naïve B lymphocytes integrate signals from two cascades for successful expansion, class 
switching and Ig secretion. Signal 1 comes from binding of native antigens to the BCR. 
Signal 2 arises from the recognition of processed antigen on MHC II by the TCR, T cell-
secreted cytokines and interaction of B cells and T cells through co-stimulatory 
molecules like CD40-CD40L [70]. The ‘two signal’ model proposed by Bretscher and 
Cohn still stands as the dogma of naïve B cell activation [71].  
 
1.4 Role of antigen properties in B cell responses 
The B cell antigen receptor recognizes antigens in their native forms with varying 
affinity, valency, chemical component and stereochemical structure. Antigen binding to 
BCR initiates cellular events that can lead to anergy, apoptosis, proliferation, 
differentiation, or memory B cell generation. The potential of the B cell to induce 
qualitatively disparate cellular responses is a result of the ability of the receptor to 
distinguish subtle differences in the nature of the ligand that interacts with it. The cellular 
response of B cells is influenced by the properties of antigens, differentiation stage of B 
cells, availability of T cell help, and environment of B cells. The relationship between 
antigen affinity and antigen-triggered responses has been extensively studied. From 
transgenic mice that expressed BCR specific for hydroxyl-nitro phenyl acetate (NP), Shih 
et al. generated mice that express BCR with high and low antigen binding affinity. High- 
and low-affinity B cells responded similarly to T-dependent antigens, although only high-
affinity B cells accumulated in the germinal center [72] and proceeded to form long-lived 
plasma cells [73]. High-affinity B cells generated a two-fold higher response to T cell-
independent antigens than low-affinity B cells [74]. Increasing antigen-BCR affinity has 
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been shown to enhance B cell antigen presenting ability, T cell-independent B cell 
proliferation, antibody secretion, and interleukin 2 and interferon-γ secretion in vitro [75, 
76].  
 
Antigen valency also influences B cell responses. When antigen valency is increased by 
conjugating BCR-specific antibodies to dextran, Ficoll, Sepharose, or polyacrylamide 
beads, the amount of antigen required for induction of B cell proliferation is reduced [77, 
78]. Increases in antigen valency synergized with CD40 ligand to induce Ig synthesis and 
isotype switching in splenic B cells [79]. Conversely, increasing antigen valency using 
biotinylated anti-BCR antibodies and avidin or by coating anti-BCR antibodies to plastic 
or erythrocyte surface induced abortive activation of B cells and apoptosis [80-82]. 
Recently, Kim et al., reported that oligomeric antigens are more effective than 
monomeric antigens in inducing rearrangement of MHC class II-containing 
compartments and enhance antigen presentation by B cells [83].  Antigen valency and 
affinity also regulate the selection of activated B cells to differentiate into short-lived 
extrafollicular antibody-secreting plasma cells or enter the germinal center. Decreasing 
antigen valency or affinity reduces the number of B cells forming extrafolliclular plasma 
cells [84]. Our published study demonstrated that increasing antigen valency increases 
the stability of BCR surface signaling microdomains, enhances the level and duration of 
antigen-triggered protein tyrosine phosphorylation, and decreases BCR internalization 
and transport [85]. Thus, the property of antigens is an important factor that regulates B 




In this dissertation, I have determined the effects of varying antigen valences on BCR 
functions. Based on published work and our previous study [85], we hypothesized that 
increasing binding valency of antigen would lead to the formation of stable BCR 
signaling microdomains that trigger strong, prolonged signaling by differentially 
recruiting signaling molecules. Using three different model antigen systems, I extended 
our previous observations by comparing the composition of BCR surface signaling 
microdomains and kinetics of recruitment of key signaling molecules to the BCR surface 
microdomains induced by antigens of varying valences.  
 
1.5 Role of Toll-like receptors (TLR) in B cell responses  
There is growing evidence of the importance of Toll-like receptors (TLRs) in the 
activation and physiology of B cells. Recent studies suggest that TLR signaling can act as 
a third signal and influence activation of naïve B cells [86, 87]. Using naïve human B 
cells, Ruprecht and Lanzavecchia showed that while BCR triggering and T cell help 
induced B cell proliferation, the cells died after 4 cycles of division. CpG ODN 
synergized with BCR stimulation and T cell help to induce sustained B cell proliferation 
[86]. Antigen-specific antibody responses in MyD88 knockout mice were observed to be 
reduced. Adoptively transferring MyD88 KO B cells into a mouse that lacks mature B 
cells, induced lower levels of IgM and IgG1 antibodies, while IgE levels were normal 
[87]. Further both human and mouse B cells required TLR stimulation for formation of 
germinal centers and differentiation of B cells to antibody-secreting plasma cells [86, 87]. 
TLRs can stimulate B cells directly or through cytokines secreted by activated dendritic 
cells and T cells. Although all TLR agonists can function as the third signal, agonists of 
 
 19
TLR2 and TLR9 activated human B cell proliferation more extensively than agonists of 
TLR3 or TLR5 [86]. Remarkably, in sharp contrast to murine B cells which can be 
activated by TLR agonists to undergo polyclonal proliferation, human B cells respond to 
TLR signaling only after receiving initial BCR stimulation. This coupling of BCR and 
TLR signaling helps to maintain specificity of the immune response by focusing innate 
immune signals on antigen stimulated B cells. 
 
Using MRL-lpr mice, a well studied model of rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE), Leadbetter et al. [88] have implicated co-ligation of TLR9 
and BCR in the pathogenesis of these autoimmune diseases. Immune complexes of self-
DNA and antibody activate self-reactive B cells by co-ligating TLR9 and BCR, leading 
to production of autoantibodies [88, 89]. The BCR seems to act as a conduit delivering 
the self DNA to the endosomal compartments where TLR9 is present. Upon extensive 
cross-linking of the BCR even DNA that lack the optimal CpG motif and are methylated 
are recognized by TLR9 and lead to antibody production [45]. Taken together these 
results suggest that extensive cross-linking of the BCR may broaden the specificity of 
TLR9 and trigger autoantibody secretion upon encountering non-immunostimulatory self 
DNA. This indicates that antigens signaling through the BCR and autoantigens through 







1.6 Toll-like Receptors 
Pathogen recognition receptors (PRRs) are involved in the innate immune response. Toll-
like receptors (TLRs) are the best characterized of the PRRs. The Toll gene in Drosophila 
was cloned as a gene that participated in dorso-ventral axis formation in the fly embryo 
[90]. Lemaitre et al. demonstrated that loss-of-function mutation in the Toll gene led to 
increased susceptibility to fungal infections in flies [4], suggesting a possible role for Toll 
in the immune response. A human homologue of Toll, Toll-like receptor (TLR) 4, was 
first cloned and characterized by Medzhitov et al. [3]. To date 10 TLRs have been 
identified in humans and 13 in mice. They differ in ligand specificities and expression 
profiles [91]. While they utilize a common signaling pathway that leads to the secretion 
of pro-inflammatory cytokines, TLRs can also activate alternate signaling pathways that 
induce pathogen-specific responses [92].  
 
1.6.1 TLR ligands 
TLRs recognize specific microbial components and initiate an immune response to 
bacteria, fungi, protozoa and viruses. TLR2 functions as heterodimer with TLR1 or TLR6 
and binds diacyl lipoproteins and triacyl lipoproteins respectively [93]. TLR4 is the 
essential receptor for lipopolysaccharide (LPS) present on Gram-negative bacteria [94]. 
TLR4 has also been shown to bind endogenous ligands like heat shock proteins, 
fibronectins, hyaluronic acid and fibrinogen when they are present in high concentrations 
[93]. TLR5 is the receptor for flagellin, a component of bacterial flagella [95]. The above 
mentioned TLRs have all been shown to be expressed on the cell surface by staining with 
specific antibodies [93]. Nucleic acids from viruses and bacteria are recognized by a host 
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of TLRs that are expressed intracellularly in endosomes. TLR3 binds to double stranded 
viral RNA (dsRNA) [96], while viral ssRNA is recognized by TLR7 and human TLR8 
[97]. TLR9 binds hypomethylated DNA sequences with CG motifs (also called CpG 
DNA) that are present in much higher frequency in prokaryotes than in eukaryotes [98]. 
A profilin-like molecule from Toxoplasma gondii is the known ligand for mouse TLR11, 
which also mediates responses to uropathogenic bacteria [99, 100].  
 
1.6.2 Structure of TLRs 
The TLRs are type I integral membrane glycoproteins with an N-terminal ectodomain 
(ECD), a single transmembrane domain and a cytoplasmic tail containing the Toll- IL-1 
and IL-18 receptor (TIR) domain [101].  
 
Individual TLR ectodomains (ECDs) can recognize multiple ligands from both 
endogenous and exogenous sources [101, 102]. Initial analysis of the TLR sequences 
indicated the presence of multiple copies of conserved leucine-rich repeats or LRRs. The 
LRR is a 24 amino acid sequence with characteristically placed hydrophobic residues. 
The LRR in the Toll-like receptors has the following consensus sequence: X L X X L X 
L X X N X φ X X φ X X X X F X X L X where X is any amino acid, L is leucine, N is 
asparagine, F is phenylalanine and φ is any hydrophobic residue [103]. Molecular models 
based on known structures of proteins like ribonuclease inhibitor, CD42b, SDS22, a yeast 
protein that contain LRR proposed that the 19-25 LRRs in the TLR ectodomain would 
form a horse-shoe shaped solenoid, with a concave surface consisting of β-strands and a 
convex surface that lacks defined secondary structure. Recent evidence from the crystal 
 
 22
structure of TLR3 supports the proposed models [104, 105]. The crystal structure also 
reveals that the N- and C- terminals of the ECDs are capped by cysteine-rich residues that 
protect and stabilize the hydrophobic core. Individual TLRs are distinguished by 
modifications of specific LRR [103]. For example, TLRs 7, 8 and 9 are characterized by 
insertions at LRRs 2, 5, 8 and 11 that differ from the consensus sequence. It has been 
suggested that these structural variations which occur on the concave part of the solenoid 
provide different TLRs the specificity to bind different ligands [103, 105]. In theory, a 
combination of insertions could give the β surface of the TLR ECD 10 times greater 
binding area than the surfaces of antibodies [103]. Another hypothesis is that the binding 
surface for TLR3, lies on the convex side, in the V-shaped valley formed upon 
dimerization of the TLRs [104]. Since TLRs have been shown to cluster hetero- and 
homo-typically even in the absence of ligands [106, 107], this raises the intriguing 
possibility that the inactive TLRs start as dimers that rearrange upon stimulation, to 
recognize specific ligands [104, 108].  
 
The cytoplasmic TIR domain is made of 200 amino acids. There are three conserved 
boxes that are crucial for signaling from the TLR. Deletion and substitution of specific 
amino acid residues in these boxes abrogates signaling activity of the receptor [109, 110]. 
Structure analysis of the TIR domains of TLR1 and 2 has been performed. The TIR 
domains contain 5 parallel β-strands flanked by 5 α-helices on both sides. The β-strands 
are connected to the α-helices by loops [111]. The TIR domains of proteins studied so far, 
show 20-30% sequence conservation. There are large insertions or deletions in several 
loop regions, which may account for the diversity in signaling initiated from the different 
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TLRs. Structural studies suggest that conserved surfaces of the TIR domain may mediate 
oligomerization of the TLRs and facilitate interactions between the TLRs and 
downstream adaptor molecules, like myeloid differentiation primary response gene 88 
(MyD88), that contain TIR domains [111]. For example, the Lpsd mutation which alters 
the sequence in one of the loops of TLR4 abolishes LPS-induced signaling, by interfering 
with a point of contact between the receptor and downstream adaptors [94].  
 
1.7 Toll-like receptor 9 and CpG DNA 
For more than a century, bacterial extracts like bacillus Calmette Guerin (BCG), have 
been used to treat cancer and allergies and more recently as vaccine adjuvants [112]. It 
was discovered that the active component of the bacterial extract that induced tumor 
regression was DNA [113], and later the consensus functional motif for this DNA was 
identified as XCGY. The C is hypomethylated (hence CpG) and X is any base other than 
C, and Y is any base but G [114]. In the vertebrate genome CG dinucleotides occur only 
at one quarter of the expected frequency due to active CG suppression. While bacterial 
and some viral DNA contain largely unmethylated cytosines, almost 70% of cytosines in 
vertebrate DNA are methylated [115]. Recognition of this structural difference between 
DNA of microbes and vertebrates is postulated to be an evolutionary mechanism of 
effective defense against pathogens. Recognition of CpG motifs triggers an immune 






1.7.1 Toll-like receptor 9  
Toll-like receptor 9 (TLR9) knockout (KO) mice do not respond to CpG DNA, 
suggesting that TLR9 is the receptor for CpG DNA [98]. Human embryonic kidney 293 
(HEK293) cells transfected with TLR9 become responsive to CpG DNA [116]. Ligand 
binding studies in these cells have shown that ssCpG DNA with phosphodiester backbone 
binds directly to TLR9 [117]. This binding is sequence-specific at acidic pH conditions, 
like those of the endosomes [117, 118]. DNA containing a phosphorothioate backbone 
can also bind TLR9 sequence non-specifically [119], although only CpG DNA activates 
TLR9 [117]. This is significant since most studies of CpG DNA use DNA with 
phosphorothioate backbone modification as this makes it resistant to nucleases and 
stimulates cells better. TLR9 is primarily expressed in B cells and plasmacytoid dendritic 
cells (pDC) in humans [112, 120]. Neutrophils [121] and epithelial cells of the lung [122] 
have also been reported to express TLR9. While murine and human NK cells [123] and T 
cells [124] secrete interferon-γ (IFN-γ) upon treatment with CpG DNA, this effect is 
indirect and depends on the presence of adherent cells or their secreted molecules [125]. 
However, the expression pattern of TLR9 in mice is different, and it has been reported to 
be expressed on macrophages and myeloid dendritic cells (mDCs) in addition to B cells 
and pDCs [120]. This divergence in expression profile of TLR9 makes it difficult to 
extrapolate the effects of CpG DNA from murine models to the human system although 
human clinical trials initiated based on preliminary research in mouse models show 





1.7.2 CpG DNA 
The optimal CpG motif for activating TLR9 expressing mouse cells is GACGTT [128] 
and for human cells it is GTCGTT [129]. Empirical studies of structure-activity 
relationships have shown that the immune response to CpG DNA is altered by the 
number and spacing of CpG motifs, modification of the backbone and presence of poly G 
motifs. Based on these studies three classes of CpG ODN have been described [130]. 
Class A ODNs typically contain a central phosphodiester backbone with 
phosphorothioate ends and poly G motifs. They induce IFN-α secretion from pDC, but 
are poor activators of pDC maturation and B cells [112]. B cells are stimulated by class B 
CpG ODN, which have fully phosphorothioate backbones. These also promote 
maturation of pDCs but do not induce IFN-α secretion [112]. The C-class CpG ODN 
have properties that are considered intermediate of A and B classes, inducing IFN-α 
secretion from pDC and activating B cells [130, 131]. Oligonucleotides that suppress 
TLR9 signaling have also been reported. The S-class ODN seem to block CpG ODN-
induced NF-κB and AP-1 activation [132, 133] and IL-12 and IFN-γ secretion [134], 
although the precise mechanism of action is not completely understood. In this 
dissertation, we have used a B-class CpG ODN (1826 or CpG DNA) and its control 
(1826GC or GpC DNA). This sequence has been shown to be an optimal activator of 







1.8 TLR9 signaling  
1.8.1 Cellular internalization of CpG ODN 
Oligonucleotides are large polyanions that cannot diffuse freely across the cell membrane. 
ODNs are taken up by cells through pinocytosis and possibly through receptor-mediated 
endocytosis [135]. While no single receptor has been implicated in this role, it is 
postulated that cell surface DNA binding proteins that bind ODNs in a sequence 
independent manner [114] might help transport them across the plasma membrane.  
CpG DNA briefly associates with the cell surface and rapidly enters into endocytic 
vesicles, presumably endosomes, near the plasma membrane in a Rab5-dependent 
process [136, 137]. This is a temperature and energy-dependent, but sequence 
independent process. Treatment of macrophages and B cells with Bafilomycin A and 
chloroquine abrogates CpG DNA-induced cellular activation [138, 139]. Bafilomycin and 
choloroquine are inhibitors of endosomal H+ ion pumps that increase endosomal pH and 
block endosomal maturation. These data indicate that the endosome is a site where CpG 
DNA initiates signaling (Fig. 1.2). in pDCs, CpG DNA is transported from cell surface 
by endosomes to tubular lysosomal structures in the perinuclear region [119]. In 
macrophages, the DNA positive vesicles co-localize with lysosome-associated membrane 
glycoprotein-1 (LAMP-1), a marker for late endosomes and lysosomes [136]. These data 
suggest that CpG enters the cell into early endosomes and rapidly moves into the 
lysosomal compartment. 
 
Endogenous and transfected TLR9 is intracellular, expressed and located in the 
endoplasmic reticulum (ER) in pDCs and macrophages [119, 140]. Flow cytometric  
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Figure 1-2. The TLR9 signaling pathway in B cells 
Oligonucleotides containing the CpG motif are internalized by B cells into endosomes. 
TLR9 encounters the ODN in late endosomal/lysosomal compartments. This initiates 
signaling from TLR9 via MyD88-IRAK-TRAF6-TAK1. TAK1 leads to the activation of 
Iκ kinase (IKK) and MAP kinases, JNK and p38. The kinases activate transcription 





































































































































































analyses of various B cell lines shows very little or no TLR9 expression on the cell 
surface [140]. Results from microscopy studies of macrophages and pDCs, show that 
upon stimulation with CpG DNA, both MyD88 and TLR9 are actively recruited to the 
CpG containing vesicles [119]. In pDCs, TLR9 is redistributed from the ER to CpG-
containing lysosomes where it initiates signal cascades [119, 141]. The mechanism of 
how TLR9 redistributes from the ER to the signaling compartment remains unclear. 
Proteins that are targeted to the plasma membrane from the ER, normally travel through 
the Golgi apparatus and the secretory pathway. The carbohydrates on these proteins 
acquire resistance to cleavage by Endoglycosidase H (Endo H), as they are modified by 
the Golgi enzymes. TLR9 that reaches the CpG-containing endosomes, remains sensitive 
to Endo H, raising the possibility that it does not pass through the Golgi [119]. Other 
possible pathways include a direct fusion of the ER to the endosome or to the plasma 
membrane.  
 
pDCs internalize CpG DNA into endosomes and transport them into tubular lysosomes as 
early as 10 min of stimulation [119]. Dendritic cells are unrivalled in their efficiency as 
antigen presenting cells. They are equipped with unique antigen presenting pathways, 
which allows them to effectively and rapidly prime naïve CD4+ and CD8+ T cells [120]. 
Naïve, resting B cells on the other hand, are not very efficient APCs. It is likely that B 
cells do not internalize and transport DNA in a similar way as the pDCs. While 
internalization of CpG DNA [114] and endosomal acidification [139] have been reported 
to be essential for CpG-induced stimulation of B cells, the kinetics and transport pathway 
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of CpG ODN in murine B cells remain to be studied. As part of this dissertation, I report 
the visualization and kinetics of the internalization of CpG ODN in mouse B cells.  
 
1.8.2 Proximal TLR9 signaling events  
Despite the diversity of ligands, TLRs activate similar signaling pathways.  Following 
internalization of CpG into endosomes, MyD88 and TLR9 are actively recruited to these 
vesicles [136]. MyD88 has emerged as a key adaptor shared by many TLRs. While some 
TLRs use MyD88-independent pathways [142], TLR9 signaling is MyD88-dependent 
and MyD88 KO mice do not respond to CpG stimulus [143]. The TLR-MyD88-IRAK4-
IRAK1-TRAF6 forms the classical TLR signaling complex and is functional in signaling 
cascades of all TLRs except TLR3 [92]. TLR activation leads to sequential 
phosphorylation of IRAK4 and IRAK1 by MyD88. IRAK1 in turn recruits and 
phosphorylates tumor-necrosis-factor receptor-associated factor 6 (TRAF6). MyD88 KO 
mice and TRAF6-deficient cells do not respond to CpG DNA stimulus, indicating their 
essential role in TLR9 signaling pathway [143]. TRAF6 activates tumor growth factor-β-
activated protein kinase 1 (TAK1), which forms a complex with TAB1, TAB2 and TAB3 
[144]. Although a direct substrate of TAK1 remains to be identified, it activates IκB 
kinase complex (IKK) and NF-κB. TAK1 is a member of the mitogen-activated protein 







1.8.3 Activation of Nuclear Factor- κB (NF-κB) 
CpG DNA-triggered TLR9 signaling pathway activates NF-κB in mature mouse splenic 
B cells and human B cells [129, 146]. Nuclear factor-κB (NF-κB) was identified 20 years 
ago as a nuclear factor that bound to the enhancer regions of the k light chain in B cells 
[147, 148]. Mammalian NF-κB family of transcription factors refers to five DNA binding 
members, p65 (Rel-A), c-Rel, RELB, p50 (a processing product of p105, also called NF-
κB1) and p52 (a processing product of p100, also called NF-κB2). These proteins form 
homo- or hetero-dimers of functional NF-κB [149]. The p65/p50 hetero-dimer is 
considered the prototypical NF-κB complex. The NF-κB family is characterized by the 
presence of the rel homology domain (RHD); which contains motifs that promote 
dimerization, DNA binding and nuclear localization. In addition to the RHD, p65, c-Rel 
and RelB also have a transactivation domain [150]. 
 
In unstimulated cells, the NF-κB dimers are rendered inactive by association with one of 
the inhibitors of NF-κB (IκB) in the cytoplasm. The IκB family comprises IκBα, IκBβ, 
IκBγ and IκBε. The IκBs interact with the NF-κB family through ankyrin repeats, block 
the nuclear localization signal of NF-κB and hold the NF-κB complex in the cytoplasm. 
Upon stimulation of the cell with CpG ODN, IκB is phosphorylated by IκB Kinase (IKK) 
complex, which leads to polyubiquitination and degradation in the proteasome. The free 
NF-κB dimers translocate to the nucleus and bind specific NF-κB binding motifs in 
promoter regions [150]. NF-κB is a key factor that regulates the transcription of genes 
related to host defense. In addition, NF-κB also activates the transcription of IκBα. Free 
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IκBα binds NF-κB in the nucleus and promotes its export to the cytoplasm via an amino-
terminal nuclear export sequence [151]. This helps restore NF-κB to its resting state. 
 
NF-κB plays an important role in innate and adaptive immune responses by controlling 
the transcription of a number of genes that are essential in host defense. NF-κB is 
activated by more than 200 different physiological stimuli and stimulates the expression 
of hundreds of target genes, including cytokines, immune receptors, regulators of cell 
cycle and apoptosis, and other transcription factors [152]. It also plays an important role 
in the generation and maintenance of mature B cells. Rel-A/p65-deficient B cells have 
greatly diminished numbers of B cells and are sensitive to TNF-mediated apoptosis [153]. 
Furthermore, NF-κB is constitutively activated in a number of human B cell lymphomas 
[154, 155] and is possibly required for maintaining the tumorigenicity of these 
lymphomas [156, 157]. The role of NF-κB in inducing growth and antagonizing cell 
death is well established. NF-κB induces the cell cycle progression by activating genes 
like cyclin D1 [158], c-myc [159] and c-myb [160]. NF-κB prolongs cell survival through 
upregulation of anti-apoptotic genes like Bcl-xl, c-IAP-1, c-IAP-2 and XIAP [161, 162]. 
Hence, NF-κB is generally considered an anti-apoptotic transcription factor; although it 
can also mediate cell death under certain conditions. T cells exposed to the oncoprotein, 
Tax, from human T-cell leukemia virus-I (HTLV-I) underwent apoptosis by upregulating 
TNF-related apoptosis inducing ligand (TRAIL) in an NF-κB -dependent fashion [163]. 
NF-κB has also been reported to upregulate Fas [164] and Fas ligand [165], while 
suppressing pro-survival genes like Bcl-xl and c-IAP [166, 167] in various cell lines. 
Thus NF-κB is a crucial mediator of cell survival and death in many types of cells, 
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including B lymphocytes and regulation of NF-κB activity can tip the balance between 
cell survival and death. 
 
CpG ODN induces the sustained activation of NF-κB and degradation of IκBα and IκBβ 
in human and murine B cells [146, 168]. The maturation of CpG DNA-containing 
endosomes results in the formation of reactive oxygen species (ROS) [139]. ROS are 
generated within 5 min of treatment with CpG DNA in B cells, and are essential for 
degradation of IκBα and I-κBβ [139] and activation of NF-κB. In human B cells, NF-κB 
was activated within one hour and the NF-κB activation was observed up to 18 hours of 
exposure to CpG ODN [129]. The sustained activation of NF-κB induced by TLR9 ligand 
has been implicated in the rescue of primary mouse splenic B cells from spontaneous 
apoptosis [146] and immature B cells from BCR-mediated apoptosis [168]. TLR9-
induced NF-κB activation promotes survival of B cells.  
 
1.8.4 Activation of Mitogen Activated Protein kinases (MAP kinases)  
CpG DNA activates mitogen activated protein kinases (MAPKs), p38, c-Jun NH2 
terminal kinase (JNK) and extracellular-signal regulated kinase (ERK). MAP kinases p38 
and JNK, but not ERK, are activated in murine and human B cells [129, 169, 170]. 
However, ERK is activated in macrophages in response to CpG stimulation [171]. JNK 
and p38 induce the phosphorylation of c-jun and activating transcription factor 2 (ATF-2) 
and activating protein 1 (AP-1) [129, 169]. In murine B cells, CpG-induced p38 and AP-




1.8.5 Transcription and translation  
Activation of MAP kinases by TLR9 ligand leads to induction of various transcription 
factors in B cells. These include activating protein -1 (AP-1), activating transcription 
factor-2 (ATF2) and cyclic AMP response element binding protein (CREB) [138, 169]. 
Protein levels of pro-survival genes like c-myc and Bcl-xl are upregulated between 1 and 
6 hours of treatment with TLR9 ligand [128, 172], while bcl-2, myn, myb and bax mRNA 
levels remain unchanged [172]. Upregulation of transcription factors and survival genes 
by CpG-containing DNA rescues mature splenic B cells from apoptosis and induces the 
secretion of cytokines like IL-12, which lead to a Th-1 type immune response.  
 
1.9 Cellular Effects of CpG DNA in B cells 
TLR9 ligand, CpG DNA, promotes polyclonal proliferation of B cells. Resting splenic B 
cells treated with CpG DNA are rescued from spontaneous apoptosis [128]. CpG ODN 
inhibits BCR-mediated apoptosis in WEHI 231, an immature B cell line [168, 172]. B 
cells that are activated through TLR9 also become sensitive to antigen stimulation and 
accelerate antigen-specific immune response [114]. CpG DNA treated B cells upregulate 
co-stimulatory molecules like MHC class II, CD80, CD86, CD40 and CD54 [129, 173]. 
Hence CpG treatment can activate B cells to undergo polyclonal proliferation in the 
absence of antigen, antigen-specific proliferation in the presence of antigen, and 
differentiation into antibody secreting cells  
 
The cellular response to CpG DNA is characterized by the secretion of pro-inflammatory, 
Th-1 biased cytokines, like interleukin- (IL) 6, IL-12, tumor necrosis factor (TNF)-α and 
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interferon (IFN)-γ [174]. CpG DNA stimulates secretion of IL-6 and IL-12 from murine 
splenic B cells [174]. IL-6 secretion in B cells depends on the ROS generated by CpG 
DNA and is sensitive to antioxidants [175]. While IL-6 has been shown to be important 
in B cell growth and differentiation, neutralizing it with antibodies does not affect CpG 
DNA induced B cell proliferation. However, CpG DNA-induced IL-6 is important for 
differentiation of B cells into IgM-secreting plasma cells [175]. In addition to pro-
inflammatory cytokines like IL-6 and IL-12, B cells also secrete anti-inflammatory 
cytokine, IL-10  [176]. IL-10 counteracts with IL-12 secreted by B cells and 
macrophages in response to CpG DNA. Immature mouse B cell line, WEHI 231 has also 
been reported to secrete TNF-α when stimulated with CpG ODN [170]. pDCs stimulated 
by CpG DNA are the primary sources of type I interferons (α and β) [177]. pDCs from 
mice and humans and monocytes from mice also secrete TNF-α, IL-6 and IL-12 [178] in 
response to TLR9 ligand.  IL-12 and IFN-α stimulate NK cells and T cells to release IFN-
γ, which can in turn activate B cells [179]. Thus, CpG DNA induces B cells and pDCs to 
secrete pro-inflammatory cytokines.  
 
In addition to provoking the release of Th-1 skewing cytokines, CpG ODN also promote 
the differentiation of B cells to plasma cells, secreting antigen-specific antibodies with 
Th1- like isotypes,  IgG2a, IgG2b and IgG3 [173]. T-bet (T-box expressed in T cells) that 
regulates transcriptional activation of Th-1- associated genetic programs is upregulated 
by CpG DNA. The upregulation of T-bet actively represses IgG1 and IgE switching in B 




Taken together, signaling through TLR9 has strong impact on B cell mediated immune 
response. CpG DNA rescues B cells from apoptosis and induces polyclonal and antigen-
specific B cell proliferation. It leads to the secretion of pro-inflammatory cytokines and 
the differentiation of B cells to plasma cells secreting Th-1 isotype of antibodies, 
inducing a predominantly Th-1 biased immune response. Hence TLR9 ligand, CpG-
containing oligonucleotides, play important roles in activating humoral immune response. 
 
1.10 Differential effects of CpG DNA on B cell subpopulations   
TLR9 is differentially expressed and activated in subsets of B lymphocytes. Naïve human 
B cells express constitutively lower levels of tlr9 mRNA compared to CD27+ memory B 
cells [181]. Both human naïve and memory B cells undergo proliferation with CpG DNA 
treatment, however, naïve B cells require the presence of antigen or BCR stimulation 
along with CpG DNA while memory B cells do not need BCR stimulation to differentiate 
to plasma cells [181]. TLR9 is also expressed in higher levels in activated human B cells. 
Human B cells that are stimulated with anti-Ig or anti-CD40 antibodies increase 
expression of TLR9 [182]. Also, transformed human B cell lines like Epstein Barr virus 
(EBV)-transformed cell lines, Burkitt lymphoma and follicular lymphoma cell lines 
express constitutively higher levels of TLR9 mRNA compared to resting untransformed 
B cells [182]. The TLR9 expression profile of different mouse B cell populations has not 
been well characterized.  
 
Malignant B cells differ in their responses to CpG ODN. Malignant B cells can 
upregulate the expression levels of costimulatory molecules like CD40, CD54, CD80, 
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CD86 and MHC class II in response to TLR9 ligand, but to levels different from primary 
B cells [183]. B-cell chronic lymphocytic leukemia (B-CLL) and marginal zone 
lymphomas are sensitive and activated strongly by CpG ODN, while plasmacytomas are 
unresponsive [184]. Follicular lymphomas, mantle cell lymphomas and large cell 
lymphomas show intermediate responses. While CpG DNA induces proliferation of 
malignant B cells, their response is generally weaker than that of primary B cells and is 
accompanied by an increase in apoptosis in some cases [184], suggesting a different role 
for TLR9 in malignant B cells.  
 
1.11 Role of TLRs in activation induced cell death  
Toll-like receptors are arguably the best-studied innate immune receptors. Signaling by 
the TLRs can induce apoptosis, yet this remains poorly characterized. While the 
physiological relevance of TLRs as death receptors remains unclear, it is speculated that 
apoptosis of activated immune cells limits their lifespan and controls the duration of the 
inflammatory response, preventing overactive inflammatory responses.  
 
Aliprantis et al., [185] first reported that activation of THP-1 cells, a monocytic cell line, 
with bacterial lipoproteins (BLPs) through TLR2 induced apoptosis. Introducing human 
TLR2 into an epithelial cell line, HEK293, by transfection induces apoptosis upon 
stimulation with BLPs. Fas associated death domain protein (FADD) was shown to be 
recruited to the death domain in MyD88 upon BLP stimulation. This activates caspase 8 
and leads to apoptosis [186]. The 19-kDa Mycobacterium tuberculosis protein, p19 [187], 
and lipoproteins from Mycoplasma fermentas [188] can also induce apoptosis by 
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signaling through TLR2. LPS through TLR4 [189], TLR-7 agonist imiquimod [190], and 
synthetic double stranded RNA (dsRNA) through TLR3 have also been shown to signal 
for apoptosis [191], especially in stimulated cells.  
 
TLR9 has been shown to be a potential death receptor. Oligonucleotides (ODNs) 
containing unmethylated CpG motifs rapidly induce apoptosis in MOLT-4 and Jurkat E6 
T leukemia cells when introduced intracytoplasmically [192, 193]. A mouse prostate 
cancer cell line, RM-1, undergoes apoptosis when treated with ODNs containing CpG 
and poly G motifs [194]. Recent studies showed that fibroblasts transfected with human 
TLR9 become sensitized to apoptosis when treated with TLR9 ligand [195]. Jahrsdorfer 
et al., have reported that biopsies of patients suffering with B cell chronic lymphocytic 
leukemia (B-CLLs) undergo apoptosis when treated with either immunostimulatory (IS) 
or non-IS ODN [196]. This indicates that CpG ODN-induced signaling can lead to 
apoptosis in stimulated cells and malignant cells. The pro-apoptotic effect of TLR ligands 
on malignant cells expressing TLRs suggests a therapeutic value of TLRs in cancer 
treatment. 
 
In this dissertation, I sought to compare and characterize the effect of CpG ODN on 
CH27 mouse lymphoma B cells and mouse splenic B cells. The murine lymphoma B cell 
CH27 was generated from the peritoneal cavity of 2a4b mice that were repeatedly 
immunized with chicken red blood cells [197]. The CH series of lymphomas is thought to 
exhibit phenotypic characteristics similar to human B cell chronic lymphocytic leukemia 
(B-CLL) [198]. Based on the previous studies mentioned above, I hypothesized that CpG 
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ODN would have differential effects on the B-CLL-like murine lymphoma B cells CH27 
and murine splenic B cells. I have also compared the activation status of down stream 
signaling components in CpG ODN-induced signaling pathways between primary B cells 
and CH27 lymphoma B cells in order to further understand the underlying mechanism for 
the differential response of lymphoma B cells and primary B cells to TLR9 ligand. Thus, 
the work described in this dissertation, compares for the first time, the differential 
response of lymphoma B cells and primary B cells to TLR9 ligand and further indicates 
that differences in NF-κB and c-myc activation by TLR9 as the potential mechanism for 
this differential response. 
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Chapter 2: Differential Responses of Mouse Primary B Lymphocytes 
and B Lymphoma Cells to Toll-like Receptor 9 Ligand 
 
2.1 Abstract 
Toll-like Receptor 9 (TLR9) recognizes microbial DNA containing unmethylated cytosyl 
guanosyl (CpG) sequences and induces innate immune responses and facilitates antigen-
specific adaptive immunity.  Recent studies reported that in addition to stimulating innate 
immunity, TLR9 ligands induce apoptosis in TLR9 expressing cancer cells.  To 
understand the mechanism for TLR9-induced apoptosis, in this study, we compared the 
effects of CpG containing oligodeoxynucleotides (CpG ODN) on mouse splenic B cells 
and a mouse lymphoma B cell line, CH27.  CpG ODN stimulated the proliferation of 
primary B cells and rescued them from spontaneous apoptosis.  In contrast, CpG ODN 
inhibited cell proliferation and induced apoptosis in CH27 lymphoma B cells in a 
sequence-specific, TLR9-dependent fashion. The lymphoma B cell apoptosis was 
accompanied by a decrease in anti-apoptotic protein Bcl-xl.  CpG ODN activated NF-κB 
and increased c-myc protein levels in both primary and lymphoma B cells, although 
CH27 cells constitutively expressed a high level of c-myc.  While the activation effects 
were robust and sustained in the primary B cells, CpG ODN-triggered NF-κB activation 
was transient in the lymphoma B cells.  Furthermore, NF-κB inhibitor, but not NF-κB 
activators or MAP kinase inhibitors, inhibited the proliferation of CH27 lymphoma B 
cells.  Our data suggest that the differential effects of CpG DNA on primary and 
lymphoma B cells occur due to differences in NF-κB activation.  The impaired NF-κB 
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activation in the lymphoma B cells results in deregulation of the balance between NF-κB 

























Toll-like receptors (TLRs) belong to a family of pattern-recognition receptors [5] that 
recognize pathogen associated molecular patterns (PAMPs), such as bacterial 
lipopolysaccharides and DNAs. The TLRs trigger innate immune responses and play a 
crucial role in limiting the early replication and spread of pathogens during an infection 
and subsequently activate antigen presenting cells, which leads to the induction of 
adaptive immune responses that provides long-lasting protection [199].  
 
Toll-like receptor 9 (TLR9) recognizes unmethylated cytosyl guanosyl (CpG) sequences 
that are present at a higher frequency in the genomes of prokaryotes than that of 
eukaryotes [114, 200]. TLR9 is primarily expressed by B cells and plasmacytoid 
dendritic cells (pDCs) in humans [201] and by macrophages and myeloid dendritic cells 
(mDCs) in addition to B cells and pDCs in mice [120]. TLR9 binds its ligand in 
endocytic vesicles, which recruits the adaptor protein MyD88 [136] and leads to the 
formation of TLR-MyD88-IRAK4-IRAK1-TRAF6 signaling complex [92].  IRAK1 
recruits and phosphorylates tumor-necrosis-factor receptor-associated factor 6 (TRAF6) 
[143]. TRAF6 activates tumor growth factor-β-activated protein kinase 1 (TAK1) [144] 
that activates IκB kinase complex (IΚK), which leads the activation of nuclear factor 
(NF) κB. TAK1 is a member of the mitogen-activated protein kinase kinase kinase 
(MAPKKK) family and is involved in the activation of MAP kinases JNK, p38 and ERK 
[145].  MAP kinase p38 and JNK, but not ERK were reported to be activated in B cells 
treated with CpG ODN [169] and contribute to the production of cytokines like IL-6 
[175], IL-10 and IL-12 [176]. Treating B cells with oligodeoxynucleotides containing 
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unmethylated CpG motifs (CpG ODNs) leads to upregulation of several transcription 
factors including NF-κB, c-myc, AP-1 and cAMP-responsive element-binding protein 
(CREB) [129, 170]  and results in a strong Th-1 biased immune response with secretion 
of pro-inflammatory cytokines like IL-6 and IL-12 [174]..   
 
CpG DNA rescues mature naive B cells from undergoing spontaneous apoptosis and 
promotes polyclonal B cell proliferation in culture [128].  This anti-apoptotic effect is 
attributed to TLR9-induced sustained activation of NF-κB and expression of  c-myc and 
Bcl-xl proteins that block the decrease of mitochondrial membrane potential [128, 146, 
172].  Signaling through TLRs has also been shown to induce apoptosis.  Bacterial 
lipoproteins signaling through TLR2, LPS through TLR4, and dsRNA through TLR3 
have been shown to induce apoptosis especially in stimulated cells [185, 191, 202].  
TLR-mediated apoptosis of activated cells has been suggested as a crucial feedback 
mechanism that down regulates TLR-induced immune cell activation and prevents an 
overactive inflammatory response that could lead to autoimmune diseases and disease 
pathologies like sepsis and airway inflammation [203]. The mechanism for TLR-induced 
apoptosis remains to be elucidated. 
 
Bacterial DNA has been used as adjuvant for generating effective antibody responses in 
animals long before the discovery of its receptor, TLR9.  Recently gained knowledge on 
the immunological functions of TLR9 uncovers the potential of CpG ODN as a human 
vaccine adjuvant and as therapeutics for cancer and autoimmune diseases [126].  It has 
been reported that CpG ODN either alone or in combination with other therapies like 
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chemotherapy and monoclonal antibodies induces tumor regression of lung and skin 
malignancies [126].  In murine models of T cell lymphoma and cervical carcinoma, 
treatment with CpG DNA induced tumor regression, which was shown to be the result of 
T cell or NK cell dependent lysis of tumor cells [204, 205]. B cell lymphomas are unique 
in that they could express TLR9 and directly respond to CpG DNA.  A recent report 
showed that CpG ODNs sensitized B cell chronic lymphocytic leukemia cells and 
fibroblasts transfected with TLR9 for apoptosis [195, 196]. These studies suggest double 
effects of TLR9 ligand on cancer cells that express TLR9, namely stimulating immune 
response against cancer cells and inducing apoptosis of cancer cells.  
 
In this study, we compared the effects of CpG ODN on a B lymphoma cell line CH27 and 
mouse splenic B cells.  We showed that CpG ODN induced apoptosis of the B cell 
lymphoma line, while stimulating proliferation and inhibiting spontaneous apoptosis of 
naïve splenic B cells in culture.  This effect is TLR9-dependent, as a variant of the 
lymphoma line that did not express TLR9 did not undergo apoptosis in response to CpG 
ODN.  By comparing the downstream signaling components activated by TLR9, we 
found that CpG ODN induced an imbalanced activation of NF-κB and c-myc in the 








2.3 Materials and Methods 
Oligonucleotides  
Nuclease-resistant phosphorothioate oligodeoxynucleotides (ODNs) – biotinylated (B) 
and unbiotinylated – were purchased from Integrated DNA Tecnologies (Coralville, IA). 
The sequence of CpG DNA used was 5’ TCCATGACGTTCCTGACGTT 3’, and this 
CpG ODN (1826) is optimal for activating mouse B cells [114]. The control non-CpG 
DNA referred to as GpC DNA was 5’ TCCATGAGCTTCCTGAGCTT 3’. Polymyxin B 
(Sigma Aldrich, St.Louis, MO) was used to eliminate the possibility of LPS 
contamination in the CpG ODN samples.  
 
Mice, cells and cell culture 
The mouse B cell lymphoma, CH27, generated and characterized by Haughton et al, 
[206] is an H-2k, IgM+, FcγRIIB1- cell line. CH27 B lymphoma cells were cultured at 
37°C in DMEM supplemented as described previously [207] and containing 15% FBS. 
    
BALB/c and C57BL/6 mice were purchased from Charles River Laboratories (Frederick, 
MD).  To obtain splenic B cells, single-cell suspensions of the splenocytes were prepared, 
and then subjected to density gradient centrifugation in Histopaque-1119 (Sigma, St. 
Louis, MO) at 2300 g for 15 min.  The lymphocyte-enriched fraction was harvested and 
washed.  The B cells were isolated by specific depletion of T cells using anti-Thy 1.2 





Antibodies and reagents 
Guinea-pig complement and Dulbecco’s modified eagle’s medium (DMEM) were 
purchased from Gibco (Grand Island, NY). Thy 1.2-specific monoclonal antibody (mAb) 
was obtained from PharMingen (San Diego, CA). Rabbit mAb against cleaved caspase 3 
(5A1) and rabbit polyclonal antibodies against Bcl-xl, pJNK, pERK, pp38 were 
purchased from Cell Signaling Technology (Beverly, MA). Rabbit polyclonal antibodies 
against p65 subunit of NF-κB and IκB and goat anti-Btk were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA). AlexaFluor-546 conjugated goat anti-rabbit IgG, 
AlexaFluor-546 conjugated streptavidin and SYTO-green were from Molecular Probes, 
Oregon. FITC-Fab fragments of goat anti-mouse IgM were from Jackson Immuno 
Research (West Grove, PA). 1D4B, a mAb specific for lysosomal associated membrane 
glycoprotein-1 (LAMP-1) was obtained from hybridomas purchased from ATCC 
(Rockville, MD).  Rabbit anti-mouse c-myc antibody, anti-phosphotyrosine mAb (4G10) 
and HRP-conjugated goat anti-rabbit IgG antibody were purchased from Upstate (Lake 
Placid, NY). Anti-Bax mAb (6A7) was from BD Biosciences (San Diego, CA). Anti- 
alpha tubulin mAb (TU-01) was obtained from Zymed Laboratories (San Francisco, CA).   
The MAP kinase inhibitors SB203580, SP600125 and PD98059 and NF-κB activation 
inhibitor, 6-Amino-4-(4-phenoxyphenylethylamino)quinazoline were from EMD 
Biosciences (San Diego, CA). LPS from Escherichia coli, Ionomycin and phorbol 






Cell proliferation assay 
CH27 B cell lymphomas (1 x 105 cells/well) and splenic B cells from BALB/c and 
C57BL6 mice (5 x 105 cells/well) were placed in 96-well plates and treated with varying 
concentrations of CpG ODN or control GpC ODN in the presence or absence of 
inhibitors, for 66 hours. 1μCi 3[H]- thymidine (MP Biomedicals, Irvine, CA) was added 
to each well for the last 18 hours of incubation. Cells were harvested and cell associated 
radiation was counted using a scintillation counter.  
 
RT-PCR analyses of tlr9 mRNA  
Total cellular mRNA was isolated from two different clones of CH27 and splenic B and 
T cells by Trizol (Invitrogen) using a manufacturer recommended protocol.  cDNA were 
generated from mRNA by SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) 
and amplified using tlr9 specific primers using Taq DNA polymerase (Invitrogen) with 
25 cycles.  Cycling conditions were 94oC for 30 sec, 55oC for 30 sec, and 68oC for 1 min. 
β-tubulin gene was amplified as a control, with 25 cycles with the cycling condition as 
94oC for 30 sec, 56oC for 30 sec, and 68oC for 1 min.  tlr9-specific primers were 5’-
GCACAGGAGCGGTGAAGGT-3’ and 5’-GCAGGGG TGCTCAGTGGAG-3’, and β-
tubulin-specific primers were 5’-TGGAATCCTGTGGCATCCA-3’ and 5’-
TAACAGTCCGCCTAGAAGCA-3’.    
Apoptosis assay 
CH27 lymphomas (1 x 105 cells/ml) and splenic B cells (4 x 105 cells/ml) were incubated 
in the absence or with 1 or 10 μg/ml of GpC or CpG ODN for 24 or 48 hours. Cellular 
apoptosis and necrosis were detected using the Vybrant Apoptosis detection kit from 
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Molecular Probes, Oregon. Briefly, 1 x 105 cells were harvested, washed with PBS and 
resuspended in Annexin Binding Buffer (10 mM HEPES, 140 mM NaCl, 2.5mM CaCl2, 
pH 7.4). Cells were then stained with AlexaFluor 488-conjugated Annexin V and 
Propidium Iodide for 20 min at room temperature. After incubation 400 μl Annexin 
Binding Buffer was added and the cells were immediately analyzed by flow cytometry 
using the FACSCalibur (Becton Dickinson, San Jose, CA). To test the effect of MAP 
kinase and NF-κB inhibitors, the cells were grown with the ODN and inhibitors for 24 
and 48 hours, harvested and processed as detailed above. 
 
Western blot analysis  
CH27 lymphomas (2 x 106 cells/ml) and splenic B cells (5x106 cells/ml) were incubated 
with medium alone or 10μg/ml ODN at 37°C for various times.  Reactions were 
terminated by pelleting the cells at 4°C, followed by lysis of cells in 1% Nonidet P-40 
lysis buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1 mM 
Na3VO4, 50 mM NaF and protease-inhibitor cocktail) for 30 min at 4°C. Equal 
concentrations of lysates were subjected to SDS-PAGE and blotted with antibodies to 
either cleaved caspase 3, IkBα, Bcl-xl, Bax, c-myc or phospho MAP kinases, followed by 
HRP-conjugated goat anti-rabbit IgG antibodies.  The blots were then stripped and 
reblotted with anti-tubulin antibodies and an HRP-conjugated secondary antibody as 
loading controls. CH27 lymphomas (2 x 106 cells/ml) were incubated with medium alone 
or 1μg/ml LPS at 37°C for various times and lysates were obtained as described above. 
These were subject to SDS-PAGE and probed with anti-IκBα antibody. Densitometry 
analysis of the blots was carried out and normalized to the density of tubulin band in the 
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same sample. The numbers were plotted and represent the fold induction from the 
normalized densitometric value of either the positive control or untreated sample.  
 
Immunofluorescence microscopy 
Cells (1 x 106/ml) were incubated with 7 μg/ml of ODNs at 37°C for varying lengths of 
time. Cells were washed with DMEM containing 6 mg/ml of BSA (DMEM-BSA) and 
adhered onto poly-L-lysine-coated slides (Sigma, St. Louis, MO) for 40 min at 4°C.  At 
the end of the incubation, cells were fixed and permeabilized with cold methanol, and 
incubated with antibody specific for the p65 subunit of NF-κB and AlexaFluor 546 
conjugated goat anti-rabbit IgG.  Cells were also incubated with SYTO-green stain for 20 
min to stain the nucleus. To visualize BCR and CpG ODN, cells were incubated with 20 
μg/ml F(ab) fragment of FITC-goat anti-mouse IgM for 10 min, washed with DMEM-
BSA and adhered onto poly-L-lysine-coated slides (Sigma, St. Louis, MO) for 40 min at 
4°C and then incubated with B-CpG DNA for 30 min at 37 °C. At the end of the 
incubation, cells were fixed with 3.7% paraformaldehyde, permeabilized with 0.05% 
saponin, and incubated with antibody specific for LAMP-1 (ID4B) and AlexaFlour 546-
conjugated goat anti-rat IgG and AlexaFlour 546-conjugated strpetavidin. Cells were 
mounted with Gel/Mount (Biomeda, Foster City, CA).  Slides were analyzed by laser-
scanning confocal microscopy (LSM 510, Zeiss) using 100 x oil immersion objective.  
The same settings on the confocal microscope were used for all experimental conditions.  
Control experiments where the primary antibody was omitted showed no significant 
staining signals. To quantify the immunofluorescence data, cells in five images randomly 
taken from slides of each of three independent experiments were counted for each time 
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point and condition.  The number of cells showing nuclear translocation of p65 subunit of 

























Differential effects of CpG DNA on proliferation of B cell lymphoma lines and 
primary B cells.   
Previous studies have shown that synthetic oligodeoxynucleotides containing 
unmethylated CpG motif (CpG ODNs) inhibited spontaneous apoptosis of splenic B cells 
[128] and sensitized human B cell chronic lymphocytic leukemia cells for apoptosis [196].  
We sought to compare the effects of CpG ODN on the proliferation of mouse lymphoma 
B cell line CH27 and murine splenic B cells.  The CH27 B cell line was established from 
lymphatic tumors of mice that were repeatedly immunized with sheep red blood cells 
[206]. CH27 cells and splenic B cells from BALB/c and C57BL/6 mice were cultured 
with varying concentrations of CpG ODN for 48 h, and the rate of cell proliferation was 
detected using  [3H]-thymidine incorporation.  An ODN with the CpG motif switched to 
GpC (GpC ODN) was used as a control. As previously reported, there was a dose 
dependent increase in proliferation of splenic B cells upon treatment with CpG ODNs, 
while the control GpC ODN failed to induce the proliferation of splenic B cells (Fig. 2-
1A).  The splenic B cells from BALB/c and C57BL/6 showed similar increases in the rate 
of proliferation in response to CpG ODN.  Surprisingly, CH27 lymphoma B cells, which 
constitutively proliferate in culture, reduced their proliferation rate as CpG ODN 
concentration increased.  When cultured in 0.5 μg/ml (0.07 μM) of CpG ODN, the 
proliferation rate of CH27 cells was reduced 60%.  No further reduction in the 
proliferation rate of CH27 cells was observed when CpG ODN concentration was over 
0.5 μg/ml, suggesting that the inhibitory effect of CpG ODN was saturable. The control 
GpC ODN did not affect the  
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Figure 2-1. Differential effects of CpG DNA on proliferation of lymphoma B cell line 
and primary B cells.  
(A) CH27 lymphoma B cell (1 x 105 cells/ml) and splenic B cells from BALB/c and 
C57B6 mice (5 x 105 cells/ml) were treated with varying concentrations of CpG ODN 
(filled symbols) or GpC ODN (open symbols) for 66 h. [3H]- thymidine (1 μCi) was 
added to each well for the last 18 hours of incubation, cells were harvested and cell 
associated radioactivity was counted using a scintillation counter.  Data represent mean 
(±S.D.) of triplicate samples. Shown are the representative results from three independent 
experiments.  Squares represent CH27 lymphoma B cells.  Triangles represent splenic B 
cells from BALB/c mice.  Diamonds represent splenic B cells from C57BL/6 mice. (B) 
CH27 lymphoma B cells (1 x 105 cells/ml) were treated with varying concentrations of 
CpG ODN (filled symbols) or GpC ODN (open symbols) in the presence or absence of 








































































proliferation of CH27 cells.  These results indicate that CH27 lymphoma B cells respond 
to CpG ODN differently from splenic B cells. 
 
To eliminate the possibility of lipopolysaccharide (LPS) contamination in the ODNs and 
ensure the ODN specificity of the anti-proliferatory effect of CpG ODN on CH27 B cell 
lymphomas, the CH27 B cell lymphomas were treated with Polymyxin B along with the 
ODNs. Polymyxin B is an antibiotic which sequesters LPS by forming PolymyxinB-LPS 
complexes, thereby suppressing the biological activity of LPS [208]. The CH27 B cell 
lymphomas treated with Polymyxin B and ODNs show very similar rate of proliferation 
compared to cells treated with CpG ODN alone (Fig. 2-1B). This rules out the possibility 
that the apoptotic effect seen in the B cell lymphomas is due to LPS contamination and 
reinforces the ODN specificity of the CpG-induced apoptosis.  
 
CpG ODN induces apoptosis in CH27 lymphoma B cells.  
One possible mechanism for inhibiting the proliferation of CH27 lymphoma B cells is the 
induction of apoptosis.  To test this hypothesis, we quantified the percentage of cells 
undergoing apoptosis by flow cytometry.  CH27 lymphoma and splenic B cells from 
BALB/c mice were treated with different concentrations (1 μg/ml or 10 μg/ml) of CpG 
ODN or control GpC ODN for 24 and 48 h.  At the end of the incubation, cells were 
stained with Alexa Fluor 488-conjugated Annexin V and propidium iodide (PI) and 
analyzed by flow cytometry.  Cells that were not stained by either Annexin V or PI were 
considered as live cells. Annexin V binds to the phosphatidyl serine present on the outer 
leaflet of the plasma membrane of apoptotic cells and cells stained with Annexin V only 
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were considered apoptotic cells. PI is impermeant to live cells and apoptotic cells, but 
binds to the nucleic acids of necrotic and dead cells [209, 210]. Splenic B cells that were 
untreated or treated with the control GpC ODN had 30% unstained live cells. CpG ODN  
treatment increased the percentage of live cells to 50% at 24 h and 60% at 48 h (Fig. 2-
2A) and reduced the percentage of apoptotic splenic B cells from 50% to less than 10% 
after 48 h of the treatment (Fig. 2-2B).  In contrast, CpG ODN treatment decreased the 
percentage of live CH27 cells from 60% to 30% after 24 h of the treatment.  The 
percentage of live CH27 cells further declined to less than 20% when the CpG ODN 
treatment was extended to 48 h (Fig. 2-2A).  Significantly, there was a concomitant 
increase in the percentage of Annexin V positive, apoptotic CH27 cells when treated with 
CpG ODN. While only 20% of GpC ODN treated cells were apoptotic, CpG ODN 
increased the percentage of apoptotic CH27 cells to more than 50% at 24 h and up to 
80% at 48 h (Fig. 2-2B).  There was no significant difference in the percentage of PI-
positive CH27 cells or splenic B cells after 24 or 48 h of treatment with CpG ODN, 
compared to untreated and GpC ODN-treated cells (Fig. 2-2C).  Taken together, these 
results show that while CpG ODN rescued splenic B cells from apoptosis, it induced 
apoptosis in CH27 lymphoma B cells. GpC ODN that does not activate TLR9 had no 
significant effect on apoptosis of both CH27 lymphoma and splenic B cells.  
 
To further confirm CpG ODN-induced apoptosis in CH27 cells, we followed the level of 
cleaved caspase-3, one of the key executioners of apoptosis. Caspase-3 is activated by the 
cleavage of its inactive zymogen form (35 kDa) into activated p17 and p12 forms, which 
is one of the hallmarks of caspase-mediated apoptosis [211].  The generation of cleaved  
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Figure 2-2. CpG induces apoptosis of B cell lymphoma line.   
CH27 B cell lymphomas (black bars) and splenic B cells (grey bars) were incubated with 
varying concentrations of GpC and CpG ODNs (1 μg/ml and 10 μg/ml) for 24 and 48 h. 
The cells were harvested, stained with Propidium Iodide (PI) and Annexin V and 10,000 
cells were analyzed by flow cytometry. The percentages of unstained cells (A), Annexin 
V positive cells (B) and PI positive necrotic cells (C) were plotted. Shown are the mean ± 
S.D. from three independent experiments. * refers to a statistically significant difference 
in percentages of cells compared to GpC ODN treated control samples (P < 0.02). (D) 
CH27 lymphoma B cell (2 x 106 cells/ml) and splenic B cells (5x106 cells/ml) were 
incubated with or without 1 or 10 μg/ml CpG for 24 h.  The cells were lysed, and the 
lysates were subjected to SDS-PAGE and Western blotting, probing with antibodies 
specific for cleaved caspase-3.  Equal amount (20 μg proteins/lane) of cell lysates were 
loaded. Blots were stripped and probed for tubulin as loading controls.  Shown are the 




































































caspase-3 was followed by Western blots. CH27 and BALB/c cells were treated for 24 h 
with CpG or control GpC ODN and lysed, and the lysates were subjected to SDS-PAGE 
and Western blot, and probed with an antibody specific for cleaved caspase-3.  CpG 
ODN treatment for 24 h resulted in increased levels of cleaved caspase-3 in CH27 
lymphoma B cells (Fig. 2-2D).  In contrast, cleaved caspase-3 was undetectable in splenic 
B cells under similar treatments.  The control GpC ODN did not increase the levels of 
cleaved caspase-3 in CH27 cells (Fig. 2-2D).  This confirms and extends our cytometry 
results that CH27 lymphoma B cells undergo caspase-dependent apoptosis in response to 
CpG ODN.  
 
The anti-proliferation and pro-apoptotic effects of CpG ODN on CH27 lymphoma B 
cells are dependent on TLR9.   
To test whether the inhibition of CH27 cell proliferation and induction of CH27 cell 
apoptosis by CpG ODN are dependent on TLR9, we compared the effects of CpG ODN 
on the proliferation of two different clones of CH27 cells that  were selected by limiting 
dilution.  Their tlr9 mRNA expression levels were determined by RT-PCR.  CH27 clone 
1 and mouse splenic B cells expressed significant levels of tlr9 mRNA.  However, tlr9 
mRNA was undetectable in CH27 clone 2 and splenic T cells (Fig. 2-3A).  In contrast to 
the anti-proliferation and pro-apoptotic effects of CpG ODN on CH27 clone 1 that 
expressed tlr9 mRNA, CpG ODN neither altered the proliferation rate (Fig. 2-3B) nor 
induced apoptosis (Fig. 2-3C) of CH27 clone 2 that did not express tlr9 mRNA.  This 




Figure 2-3. The anti-proliferation and anti-apoptotic effect of CpG ODN on CH27 
lymphoma B cells are mediated through TLR9.   
(A) Total cellular mRNA was isolated from two CH27 lymphoma clones and splenic B 
(B) and T (T) cells from BALB/c mice using Trizol. TLR 9 mRNA was amplified by RT-
PCR. Tubulin mRNA was also amplified as a control.  (B) CH27 lymphoma B cells clone 
1 and 2 (1 x 105 cells/ml) were treated with varying concentrations of CpG ODN for 66 h.  
The cell proliferation was analyzed by [3H]- thymidine incorporation as described in 
Figure 2-1.  Data represent mean (±S.D.) of triplicate samples. Shown are the 
representative results from three independent experiments. (C) CH27 lymphoma B cells 
clone 2 was treated as described in Figure 2-2 and the percentage of live and apoptotic 




































































Differential effects of CpG ODN on the expression of apoptosis regulatory proteins 
in CH27 lymphoma and splenic B cells.   
The Bcl-2 family of proteins is critical in maintaining mitochondrial integrity and 
regulating apoptosis.  Bcl-xl and Bax are two major apoptotic regulators in B cells [212], 
with Bcl-xl being an anti-apoptotic and Bax, a pro-apoptotic member of the Bcl-2 family.  
Stimulation with CpG DNA has been reported to increase Bcl-xl protein levels and 
rescue splenic B cells from apoptosis [172]. To understand how TLR9 induces the 
apoptosis of CH27 lymphoma B cells, we compared the effect of CpG ODN on the 
protein levels of Bcl-xl and Bax in CH27 and splenic B cells by Western blot.  CH27 
constitutively expressed high levels of Bcl-xl (Fig. 2-4, top panel, lane 1), similar to other 
lymphoma B cells [213].  CpG ODN-treatment decreased Bcl-xl expression level, and 
this decrease was observed as early as 12 h of CpG treatment (Fig. 2-4, top panel, lane 2).  
In contrast, freshly isolated naïve splenic B cells had no detectable level of Bcl-xl (Fig.2-
4, bottom panel, lane 1), and showed an increase in Bcl-xl expression level after 24 and 
36 h of CpG treatment (Fig. 2-4, bottom panel, lane 3, 4).  CpG ODN treatment did not 
result in any significant change in Bax protein levels in CH27 B lymphoma cells (Fig. 2-4, 
top panel, lane 1- 7).  This indicates that CpG ODN differentially regulates the protein 
expression levels of Bcl-xl in B lymphoma CH27 cells and splenic B cells, which could 






Figure 2-4. Differential effects of CpG DNA on the expression levels of Bcl-xl and 
Bax in lymphoma and primary B cells.   
CH27 clone 1 (2 x 106 cells/ml) and splenic B cells (5 x 106 cells/ml) were cultured in the 
absence or presence of 10 μg/ml CpG or GpC ODN for 12, 24 and 36 h.  The cells were 
lysed and lysates subjected to SDS-PAGE and Western blotting.  Blots were probed with 
anti-Bcl-xl and anti-Bax antibodies followed with HRP-conjugated secondary antibodies.  
Equal amount (30 μg protein/lane) of the cell lysates was loaded.  Blots were stripped 
and probed with antibody against tubulin, which serves as a loading control.  Shown are 






































Differential effects of CpG ODN on the activation of NF-κB in CH27 lymphoma and 
splenic B cells.   
NF-κB is the main downstream target of TLR9 signaling pathway [146, 170] and a key 
regulator of B cell fate.  Next, we tested whether CpG ODN induces differential levels of 
NF-κB activation by following the nuclear translocation of NF-κB p65 subunit and 
degradation of the inhibitory component of NF-κB, IκBα.  The nuclear translocation of 
NF-κB p65 was followed by immunofluorescence microscopy.  CH27 lymphoma and 
splenic B cells were treated with CpG ODN (7 μg/ml) or control GpC ODN for varying 
lengths of time.  At the end of each time point, the cells were fixed, permeabilized, and 
stained with a mAb specific for the p65 subunit of NF-κB and a DNA dye.  There was a 
minimal and similar basal level of NF-κB p65 in the nuclei of both splenic and CH27 
lymphoma B cells. The nuclear staining levels of p65 in both B cell types were increased 
after 15 and 45 min of treatment with the CpG ODN (Fig. 2-5B).  NF-κB p65 staining 
level in the nuclei of splenic B cells continued increasing with nearly 80% of the splenic 
B cells exhibiting NF-κB nuclear translocation after 120 min of treatment with CpG 
ODN (Fig. 2-5Aj – l).  However, in the CH27 lymphoma B cells, NF-κB p65 staining 
level in the nuclei returned to the basal level after 120 min of CpG ODN treatment with 
only 20% of the cells showing NF-κB nuclear translocation (Fig. 2-5Ad – f).   
 
The degradation of the inhibitory component of NF-κB, IκBα, was followed by Western 
blot. CpG ODN treatment induced a continuous decrease of IκBα in splenic B cells up to 
2 h.  However, in CH27 lymphoma B cells the same treatment resulted in a transient 
decrease of IκBα level at 30 min, but returned to basal level by 90 min (Fig. 2-5C, top 
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Figure 2-5. Differential effects of CpG DNA on NF-κB activation in lymphoma and 
primary B cells.   
(A) CH27 clone 1 (a – f) and splenic B cells (g – l) (1 x 106 cells) were treated with 
7μg/ml CpG or GpC DNA for various times at 37°C.  The cells were then fixed, 
permeabilized, and incubated with a mAb specific for p65 subunit of NF-κB and Alexa 
Fluor 546-conjugated secondary antibody.  Cells were also incubated with SYTO-green 
to stain the nucleus. Images were acquired in the middle of the cells using a confocal 
fluorescence microscope.  Shown are representative images of cells after 2 h of exposure 
to ODNs. Bar, 10 μm.  (B) Shown is a quantitative analysis of the effect of CpG ODN on 
translocation of p65 subunit of NF-κB to the nucleus.  Hundred cells were counted from 
five random fields of each time point of three independent experiments.  The percentages 
of CH27 lymphomas and splenic B cells showing translocation of the p65 subunit of NF-
κB to the nucleus upon exposure to CpG (black bars) or GpC (grey bars) DNA is plotted. 
Shown is the mean ± S.D. from three independent experiments.  (C) CH27 lymphomas 
clone 1 (2 x 106 cells/ml) and splenic B cells (5x106 cells/ml) were treated with 10 μg/ml 
CpG and GpC DNA for various times (30 min to 2 h).  After stimulation, cells were lysed 
and the lysates subjected to SDS-PAGE and Western blot, probing with anti-IκBα 
antibody and an HRP-conjugated secondary antibody. Equal amounts (30 μg 
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panel, lane 2 - 4).  The control GpC ODN did not alter the protein levels of IκBα in either 
cell type (Fig. 2-5C, lane 6 - 9).  These results showed that CpG ODN induced a 
sustained increase of NF-κB activation in splenic B cells, but only a transient activation 
of NF-κB in CH27 lymphoma B cells. 
 
Effects of NF-κB activators and inhibitor on the proliferation of CH27 lymphoma B 
cells and splenic B cells.   
CpG ODN treatment of CH27 induced a transient activation of NF-κB, which was 
concurrent with a decrease in cell proliferation and an increase in apoptosis. To further 
test the involvement of NF-κB in CpG ODN-induced apoptosis, we determined the effect 
of NF-κB activators and inhibitor on the proliferation of the two types of B cells. In B 
cells upon BCR ligation, protein kinase C functions as a major upstream activator of NF-
κB [214].  To activate protein kinase C, we treated CH27 cells with varying 
concentrations of phorbol myristate acetate (PMA), ionomycin and a combination of the 
two.  The protein kinase C activators slightly increased the proliferation rate of CH27 
cells (Fig. 2-6A). A cell permeable quinazilone compound was used as NF-κB inhibitor. 
This compound has been shown to inhibit NF-κB transcriptional activation in Jurkat cells 
with no cytotoxicity even at high concentrations [215]. CH27 B cell lymphomas and 
splenic B cells were treated with varying concentrations of the NF-κB inhibitor in the 
presence of CpG or control GpC ODN. The combination treatment of CpG ODN and NF-
κB inhibitor induced a stronger inhibition of CH27 proliferation than CpG ODN alone 
(Fig. 2-6B). CpG-induced proliferation of splenic B cells was also drastically inhibited 
when the cells were treated  
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Figure 2-6. Effect of NF-κB activators and inhibitor on proliferation of lymphoma 
and primary B cells.  
CH27 clone 1 cells were treated with varying concentrations of PMA or ionomycin or 
PMA and ionomycin (A) or CH27 clone 1 cells and splenic B cells with varying 
concentrations of NF-κB inhibitor in the presence or absence of 2.5 μg/ml of GpC or 
CpG ODN (B) or CH27 clone 1 cells and splenic B cells were treated with varying 
concentrations of CpG or GpC DNA in the presence or absence of 5nM NF-κB inhibitor 
(C). The rate of proliferation of the cells was determined as described in Figure 2-1 
except in (C) where the cells were harvested after 24 or 48 h of treatment. Data represent 
mean (± S.D.) of triplicate determinations.  Shown are the representative results from 
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with NF-κB inhibitor (Fig. 2-6B). Furthermore, when CH27 and splenic B cells were 
treated with different concentrations of CpG or GpC ODN in the presence of NF-κB 
inhibitor similar reduction in rates of proliferation was observed (Fig. 2-6C). Hence, the 
NFkB inhibitor exacerbated the anti-proliferation effect of CpG ODN in the CH27 B cell 
lymphomas suggesting that CpG ODN-induced CH27 cell apoptosis is associated with 
the inhibition, but not the transient activation of NF-κB. This also indicates that NF-κB is 
crucial for CpG-induced proliferation in B cells.  
 
Differential effects of CpG ODN on the expression levels of c-myc in splenic and 
CH27 lymphoma B cells.   
c-myc is one of the key regulators in cell proliferation and survival. CpG DNA has been 
reported to induce an increase in c-myc protein levels, conferring a pro-survival and anti- 
apoptotic effect on splenic B cells [172].  On the other hand, one of the major causes of B 
cell lymphoma, such as Burkitt’s lymphoma, is the aberrant translocation of the c-myc 
gene to the immunoglobulin heavy chain locus during recombination events, which leads 
to constitutive expression of c-myc [216].  To compare the effect of CpG DNA on c-myc 
expression in CH27 lymphomas and splenic B cells, cells were treated with 10 μg/ml 
CpG ODN or control GpC ODN for 1, 6, 12 and 24 h, and the lysates were subjected to 
Western blot analyses to determine c-myc protein levels.  As observed in many other B 
lymphomas [217], there was a high level of constitutively expressed c-myc protein in 
unstimulated CH27 lymphoma B cells (Fig. 2-7A, top panel, lane 2, and Fig. 2-7B), 
compared to the resting splenic B cells (Fig. 2-7A, bottom panel, lane 2, and Fig. 2-7B).  
Treating CH27 lymphoma B cells with CpG ODN increased c-myc protein levels at 6 h,  
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Figure 2-7. Differential effects of CpG DNA on expression level of c-myc in 
lymphoma B and primary B cells.  
(A) CH27 lymphoma B cell clone 1 and splenic B cells were treated with or without 10 
μg/ml of GpC or CpG ODNs for specified times.  Cells were then lysed and the lysates 
were subjected to SDS-PAGE and Western blotting, probed with anti-c-myc antibody and 
an HRP-conjugated secondary antibody.  Shown is a representative blot of five 
independent experiments. P refers to a positive control of HeLa cell lysate.  (B) The 
relative amount of c-myc protein expressed in CH27 lymphoma B cells clone 1 (black 
bars) and splenic B cells (grey bars) in (A) was quantified by densitometry and 
normalized to the relative amount of tubulin in the same sample.  The results were plotted 
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followed by a significant decrease in c-myc protein at 12 h to a level less than the 
constitutive level at 24 h (Fig. 2-7A, top panel, lane 3 - 6, and Fig. 2-7B).  However, CpG 
ODN treatment induced a sharp increase in c-myc expression in the splenic B cells, 
which became detectable at 1 h and continued to increase at 12 h after exposure to CpG 
ODN (Fig.2- 7A, bottom pane, lane 3 - 6, and Fig. 2-7B).  Control GpC ODN had no 
significant effect on the expression of c-myc in both the cell types (Fig. 2-7A, lane 7 - 10, 
and Fig. 2-7B).  Thus, CpG ODN treatment of CH27 lymphoma B cells that 
constitutively express a high level of c-myc, induced a transient increase, followed by a 
drastic decrease in c-myc protein levels, while inducing an increase in c-myc expression 
levels in primary splenic B cells. 
 
CpG ODN-induced apoptosis in lymphoma B cells is independent of MAP kinases.  
MAP kinases JNK and p38, which are activated by TLR9-induced signaling cascades in 
B cells, are important regulators of stressed-induced apoptosis [169, 170]. To test 
whether MAP kinases are involved in CpG ODN-induced apoptosis, we analyzed the 
effect of CpG ODN on the activation levels of ERK, JNK and p38 and the effect of MAP 
kinase inhibitors on the proliferation and apoptotic response of CH27 B cells to CpG 
DNA.  The activation of the MAP kinases in CH27 and BALB/c splenic cells treated with 
CpG ODN was analyzed by Western blot analyses.  CH27 lymphoma B cells had a 
constitutively high level of phosphorylated JNK (pJNK) and ERK (pERK) (Fig. 2-8, top 
panel, lane1).  The levels of pJNK and pERK were significantly decreased after a 30 min 
treatment with CpG ODN and continued to decrease at 60 min (Fig. 2-8A, top panel,  
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Figure 2-8. CpG ODN-induced apoptosis in B cell lymphoma line is independent of 
MAP kinases.   
(A) CH27 B cell lymphomas clone 1 and splenic B cells were treated with or without 10 
μg/ml of GpC and CpG ODNs for specified times. Cells were then lysed and the lysates 
were subjected to SDS-PAGE and Western blotting.  The blots were probed with 
antibodies specific for the phosphorylated forms of ERK or JNK or p38 and HRP-
conjugated secondary antibodies.  Shown are representative blots of five experiments. 
Lysates of splenic B cells that were stimulated by cross-linking the surface BCR with 
anti-Ig antibodies were used as positive control, P (B and C) The relative amount of 
phosphorylated MAP kinase protein expressed in CH27 lymphoma B cells clone 1 (B) 
and splenic B cells (C) in (A) was quantified by densitometry and normalized to the 
relative amount of tubulin in the same sample. The results were plotted as the fold of 
densitometric value of the positive control, P. (D) CH27 B cell lymphomas clone 1 was 
incubated with increasing concentrations of JNK or p38 inhibitors (1, 5 and 10 μM) in 
the presence of CpG or GpC DNA (10 μg/ml).  Rate of apoptosis induction was 
determined as described in Figure 2-3.  Shown are the percentages (± S.D.) of Annexin V 
positive apoptotic cells from three independent experiments.  (E) CH27 B cell 
lymphomas clone 1 was incubated with increasing concentrations of inhibitors specific 
for JNK, ERK, and p38 in the presence of GpC (dotted lines) or CpG (straight lines) 
ODN (10 μg/ml).  Cell proliferation was determined as described in Figure 2-1.  Data 
represent mean (±S.D.) of triplicate samples.  Shown are the representative results from 
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lane 2 - 5 and Fig. 2-8B). Phosphorylated JNK was undetectable in untreated splenic B 
cells and briefly detected at 7 min after CpG ODN treatment (Fig. 2-8A, bottom panel 
lane 2 and Fig. 2-8B), while phosphorylated ERK was undetectable at all time points 
tested (Fig. 2-8A, bottom panel, lane 1 - 9 and Fig. 2-8C). CH27 lymphoma B cells and 
splenic B cells have constitutively low level of phsophorylated p38 (Fig. 2-8A, top and 
bottom panel, lane 1, Fig. 2-8B and Fig. 2-8C). The p38 levels in CH27 lymphoma B 
cells do not change upon treatment with CpG ODN (Fig. 2-8A, top panel, lane 1 - 9 and 
Fig. 2-8B), while it appears to be upregulated in splenic B cells at 30 min of treatment 
(Fig. 2-8A, bottom panel, lane 4 and Fig. 2-8B).  
 
To inhibit MAP kinase activation, CH27 cells were treated with varying concentrations 
of inhibitors of JNK (SP600125) and p38 (SB203580) [170] in the presence or absence of 
10 μg/ml CpG or GpC ODN.  Compared to cells treated with CpG ODN alone, addition 
of the inhibitors did not significantly change the proliferation rate (Fig. 2-8E) or 
apoptosis level (Fig. 2-8D) of CH27 cells.  Furthermore, treating CH27 cells with 
inhibitor specific for ERK activation (PD98059) in the presence or absence of CpG or 
GpC ODN did not affect the proliferation rate of CH27 cells (Fig. 2-8E).  This suggests 
that CpG ODN-induced apoptosis in CH27 lymphoma B cells is independent of MAP 
kinases JNK, ERK, and p38. 
 
Effect of LPS on CH27 B cell lymphomas. 
Lipopolysaccharide (LPS) found on the cell walls of Gram negative bacteria is a potent 
stimulus for B cell proliferation [40]. LPS binds Toll-like receptor 4 (TLR4) and activates 
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NF-κB through a MyD88-dependent signaling pathway [218]. We tested the effect of 
LPS on the CH27 lymphoma B cells. CH27 B lymphoma cells were cultured in the 
absence of or with varying concentrations of LPS for 48 h, and the rate of cell 
proliferation was detected using  [3H]-thymidine incorporation. Similar to treatment with 
CpG ODN, increasing concentrations of LPS induced a sharp decrease in the 
proliferation of the lymphomas, compared to untreated cells (Fig. 2-9A). LPS induces 
NF-κB activation in B cells similar to CpG ODN. To follow the activation of NF-κB, the 
degradation of the inhibitory component of NF-κB, IκBα, in CH27 lymphomas treated 
with LPS was followed by Western blot. LPS induced a transient decrease of IκBα level 
at 30 min, but returned to basal level by 120 min in the CH27 lymphomas (Fig. 2-9B), 
while the untreated samples did not alter the protein levels of IκBα (Fig. 2-9B).  
 
Taken together these data suggest that like CpG ODN, LPS inhibits the proliferation of 
CH27 lymphomas and causes transient NF-κB activation.  
 
B cell lymphoma cells internalize and transport CpG DNA to late endosomes. 
The different cellular responses of B lymphomas and splenic B cells to CpG ODN might 
occur due to different or impaired internalization of CpG ODN in the CH27 B 
lymphomas. To test this, we followed the internalization of biotinylated CpG by 
immunofluorescence microscopy. Surface IgM, which is known to rapidly internalize and 
move to late endosome upon cross-linking [219], was stained as a control in both cell 




Figure 2-9. Effect of LPS on CH27 B cell lymphomas 
(A) CH27 B cell lymphomas clone 1 was incubated with increasing concentration of LPS. 
Cell proliferation was determined as described in Figure 2-1.  Data represent mean 
(±S.D.) of triplicate samples.  Shown are the representative results from three 
independent experiments. (B) CH27 lymphomas clone 1 (2 x 106 cells/ml) was treated in 
the presence or absence of 1μg/ml LPS for various times (30 min to 2 h). Lysates were 





















































Figure 2-10. B cell lymphoma cells internalize and transport CpG DNA to late 
endosomes.  
CH27 lymphomas (Aa – Ac) and splenic B cells (Ad – Af) were treated with 7μg/ml 
biotinylated CpG and FITC goat anti-IgM for various times at 37°C. The cells were then 
fixed, permeabilized and incubated with AlexaFluor 546- streptavidin alone (A) and anti-
mouse LAMP-1 mAb (ID4B) and goat anti-mouse IgG secondary antibody (B). Images 
were acquired in the middle of the cells using a confocal fluorescence microscope. 





































CH27 B cell lymphomas (Fig.2-10Aa – Ac) and splenic B cells (Fig.2-10Ad - Af), 
indicating no significant difference in the internalization of the ODNs between primary 
splenic B cells and B lymphoma cells. Dendritic cells and macrophages have been shown 
to internalize CpG ODN and traffic them to LAMP-1 positive late endosome/lysosomes 
compartments [119, 136]. To determine the cellular distribution of internalized CpG 
ODN in the CH27 B cell lymphomas, the late endosomal/lysosomal compartments were 
visualized with anti-LAMP-1 mAb. At 30 min, CpG ODN co-localizes with LAMP-1 
positive late endosomal/lysosomal compartments (Fig 2-10Bd), indicating that 


















The recognition of common molecules present on microbial pathogens by Toll-like 
receptors initiates innate immune responses.  Recent studies showed that the binding of 
ligands to TLR2, 3, 4, 6 and 9 leads to the apoptosis of cancer cells and activated 
macrophages [188, 189, 191, 196].  While TLR-induced cell death has been suggested to 
be a negative feedback mechanism for preventing over-activated inflammatory responses 
[203], its underlying mechanisms and physiological significance remain to be elucidated.  
This study examined the differential effects of TLR9 ligand, CpG ODN, on naïve mouse 
splenic B cells and mouse lymphoma B cells and explored the underlying mechanism for 
the pro-apoptotic function of TLR9. It was found that while it promoted the proliferation 
of splenic B cells, TLR9 ligand, CpG ODN, induced apoptosis in CH27 lymphoma B 
cells.  CpG ODN-induced apoptosis was associated with an transient activation of NF-κB, 
an increase of c-myc over an already high level of constitutively expressed c-myc, and 
decreases in the levels of anti-apoptotic molecule Bcl-xl and phosphorylated MAP kinase 
JNK that were constitutively high in CH27 cells.  
 
Several recent publications have reported TLR9-triggered cell death.  Fischer et al. 
showed that TLR9 ligand sensitized a TLR9-transfected fibroblast cell line for apoptosis 
[195]. Jahrsdorfer et al. recently reported that cells from biopsy samples of patients 
suffering from B cell chronic lymphocytic leukemia (B-CLL) underwent apoptosis when 
treated with CpG ODN [196].  Similar to these reports, we found in this study that CpG 
ODN induced apoptosis of a mouse B cell lymphoma line, CH27.  This further supports a 
pro-apoptotic effect of TLR9 ligands on tumor cells that express TLR9.   
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The CH27 murine B cell lymphoma was generated from the peritoneal cavity of 2a4b 
mice that were repeatedly immunized with chicken red blood cells [197].  CH27 cells 
predominantly express mIgM that is specific for phosphorylcholine [198], suggesting that 
it originated from B1 lineage.   Here we showed that CH27 cells constitutively express 
high levels of Bcl-xl and c-myc, two genes that are commonly deregulated in cancer cells 
and translocated to Ig H locus in cancer B cells, such as human Burkitt's lymphoma [220].  
The CH series of lymphomas was also thought to exhibit phenotypic characteristics 
similar to human B cell chronic lymphocytic leukemia (B-CLL) [198].  It has been 
suggested that B-CLLs arise due to chronic antigenic stimulation, most probably from 
autoantigens [221]. Surface immunoglobulins of B-CLLs react with self-antigens like 
DNA and Ig [222]. There has been at least one case of B-CLL expressing IgM specific 
for phosphatidylcholine [223]. Hence the CH27 B lymphomas can serve as an in vitro 
model to understand the underlying mechanism for the pro-apoptotic functions of TLR9 
on B cell cancers.  
 
Our results showed that only CpG ODN that contained the CpG motif, but not GpC ODN 
that had the CpG motif inverted, exhibited immunostimulatory and pro-apoptotic effect.  
While GpC ODN has served as an ideal negative control for our experiments, the results 
from these experiments also allude to the sequence specific nature of these effects.  In 
addition, we found that CpG ODN only induced apoptosis in CH27 B cell lymphoma 
cells that express TLR9 mRNA, but had no effect on the cell proliferation and apoptosis 
of a variant of the CH27 cells that does not express TLR9.  This demonstrates that CpG 
ODN-induced apoptosis in CH27 lymphoma B cells is mediated by TLR9. Interestingly, 
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CH27 lymphoma B cells that were treated with lipopolysaccharide (LPS) which activates 
TLR4, also showed a similar reduction in rate of proliferation. TLR4 activates MyD88 
pathway, similar to CpG ODN. This suggests that both CpG ODN and LPS utilize a 
common TLR pathway to induce their anti-proliferative effects.  
 
To further understand the mechanism for CpG ODN-induced apoptosis of CH27 
lymphoma B cells, we compared the effect of CpG ODN treatment on the levels of 
cleaved caspase 3, an executioner caspase, and two major Bcl-2 family proteins, Bcl-xl 
and Bax that regulate the mitochondrial stability, in the two types of cells.  Bcl-xl is an 
anti-apoptotic and Bax a pro-apoptotic protein.  Our data showed that CpG ODN induced 
the cleavage of caspase 3 in CH27 lymphoma B cells, but not in splenic B cells, 
suggesting that CpG ODN-induced apoptosis in CH27 cells is mediated by a caspase-
dependent pathway.  In untreated CH27 cells, we detected a significant level of Bcl-xl, 
and the constitutive expression of Bcl-xl is likely to be part of tumorigenic mechanisms 
in CH27 cells.  Instead of increasing Bcl-xl protein levels as seen in naïve primary B cells, 
CpG ODN treatment drastically decreased Bcl-xl protein levels in CH27 lymphomas. 
Because Bcl-xl is essential for protecting the integrity and stability of mitochondria and 
inhibiting mitochondria-mediated apoptosis pathway, a drastic decrease in Bcl-xl could 
be a direct course for the apoptosis of the CH27 B cell lymphomas by destabilization of 
mitochondria.  CpG ODN treatment had no significant effect on Bax protein levels in 
CH27 cells.  Unaltered Bax level does not exclude it from playing a role in CpG ODN-
induced apoptosis since the activation of Bax during apoptosis generally does not require 
an increase in its expression level [224].  The Bcl-2 family comprises many members, 
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including Bax, Bak, Bok, Bid, Bad, Bim, Puma and Noxa [225].  In addition to Bcl-xl 
and Bax, the other members of the Bcl-2 family could also play roles in CpG ODN-
induced apoptosis of CH27 lymphomas.   
 
NF-κB and c-myc have emerged as two key transcription factors that regulate the balance 
between cell proliferation and apoptosis [226, 227].  NF-κB is crucial for host defense 
[152] and essential for B cell survival during B cell development and differentiation 
[153]. Besides activating genes encoding for cytokines and immune receptors, NF-κB 
induces the transcription of cell cycle regulators, like cyclin D1 [158] and c-myc [159], 
and anti-apoptotic genes like Bcl-xl [161, 162], which promote cell cycle progression and 
cell survival.  The NF-κB family comprises multiple members, and Rel-A/p65 is a major 
member of the NF-κB family expressed in B cells.  Rel-A/p65-deficient mice have 
greatly diminished numbers of B cells and are sensitive to TNF-mediated apoptosis [153].  
c-myc induces the expression of cell cycle proteins and is essential for the progression of 
G1 stage of the cell cycle [228]. NF-κB or c-myc has been found to be constitutively 
activated or expressed in a number of human B cell lymphomas and have been implicated 
for tumorigenesis [229].  Paradoxically, inappropriate activation of Myc and NF-κB can 
also promote or sensitize cells to apoptosis [230].  Myc has long been known as an 
inducer of apoptosis [230, 231].  Recent studies have provided strong evidence that cell 
proliferation induced by Myc in the absence of sufficient levels of anti-apoptotic signals 
leads to apoptosis (see review [232, 233]).  NF-κB has been shown to induce apoptosis in 
certain types of cells stimulated under specific conditions (see review [161]).  Both NF-
κB (see review [161]) and c-myc (see review [232]) can induce apoptosis by directly or 
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indirectly regulating the expression levels of apoptotic regulators like Bcl-xl, cell cycle 
checkpoint protein like p53, and death receptors like CD95.  Cooperation between NF-κB 
and c-myc is essential for controlling cell fate.  c-myc induced cell death was 
accompanied by impaired activation of NF-κB and release of cytochrome c from the 
mitochondria [234] and over expression of the p65 subunit of NF-κB rescued cells from 
c-myc dependent cell death [235].   
 
In this study, we found that CpG ODN-induced apoptosis in CH27 B cell lymphoma was 
concurrent with a transient increase and a subsequent rapid decrease in NF-κB activity 
and c-myc protein level, which is in sharp contrast with naïve splenic B cells where CpG 
ODN induced a steady increase in NF-κB activity and c-myc protein level.  Another 
important difference that we observed between CH27 cells and splenic B cells is that 
CH27 cells, but not splenic B cells, constitutively express a significant level of c-myc.  
CpG ODN treatment further increased the c-myc protein level around 6 h.  Differing 
from a previous report [236],  we did not observe constitutive activation of NF-κB in 
CH27 cells.  After transient activation by CpG ODN, NF-κB activation level rapidly 
decreased; returning to the basal level at 90 min. LPS treatment also induced a similar 
transient activation of NF-κB in the CH27 lymphoma B cells.  Following the decrease in 
NF-κB activity, c-myc protein level also decreased to the constitutive level at 12 h and to 
a level lower than the constitutive level by 24 h in the lymphoma cells treated with CpG 
ODN.  Interestingly, a similar correlation between the activity level of NF-κB and c-myc 
expression level during B cell antigen receptor-triggered apoptosis in an immature B cell 
lymphoma line, WEHI 231, were reported [237, 238].  These observations point to the 
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deregulation of NF-κB and c-myc as a mechanistic cause of CpG ODN-induced 
apoptosis in CH27 cells. LPS-induced transient NF-κB activation in CH27 lymphoma 
cells, suggests that the reduction in proliferation of CH27 cells might occur by a similar 
deregulation of NF-κB activation. Based on previous studies and the data presented here, 
we propose several possible mechanisms for CpG ODN-induced apoptosis.  First, CpG 
ODN-induced NF-κB activation may trigger apoptosis, secondly CpG ODN-induced 
aborted activation of NF-κB causes the down-regulation of anti-apoptotic genes, leading 
to apoptosis, and thirdly CpG-ODN-induced further elevation of c-myc protein over its 
constitutively high level may cause apoptosis.  
 
To test whether CpG ODN-induced CH27 apoptosis is due to the initial hyper-activation 
or the later hypo-activation of NF-κB, we tested the effect of activating NF-κB through 
protein kinase C and inhibiting NF-κB activation on CH27 cell proliferation.  We found 
that activating protein kinase C slightly increased CH27 cell proliferation, and NF-κB 
inhibitor further enhanced the inhibitory effect of CpG ODN on CH27 cell proliferation 
and decreased CpG-induced proliferation of splenic B cells. This indicates that CpG 
ODN-induced apoptosis of CH27 cells is, at least in part, the result of hypo-activation of 
NF-κB.  Our data showed that while NF-κB activity was rapidly reduced, c-myc protein 
level remained high.  Imbalance between the decreasing activity of NF-κB and a 
constitutive high level of c-myc could generate a situation, where cell proliferation 
induced by c-myc in the absence of sufficient anti-apoptotic signals from NF-κB, 




TLR9-mediated signaling pathway activates MAP-kinase JNK and p38 in B cells [169, 
170], which are also important apoptotic regulator in B cells.  Stress-induced activation 
of JNK and p38 often leads to apoptosis through activation of mitochondrial apoptotic 
pathway [239, 240]. NF-κB activation suppresses JNK activation, which protects cells 
from apoptosis [241] and p38 suppression by use of pharmacological inhibitors leads to 
apoptosis [242]. However, apoptosis induced by over-expression of c-myc has been 
reported to associate with a decrease in JNK phosphorylation, and c-myc can inhibit 
upstream kinases of MAP kinases, like MEKK1, impairing both the NF-κB and JNK 
activation [235]. Paradoxically, many human and mouse B cell lymphomas constitutively 
express high levels of active JNK, and the survival and proliferation of these B cell 
lymphomas depend on JNK activation [243]. In this study, we found that JNK was 
constitutively activated in CH27 cells, similar to other lymphoma B cells. CpG ODN 
treatment significantly reduced the level of phosphorylated JNK but did not activate p38 
in the CH27 lymphomas. Post-translational stability of c-myc is controlled by 
phosphorylation of specific serine or threonine residues of c-myc protein. ERK increases 
stability of c-myc potein by phosphorylating serine 62 [244]. We found that ERK was 
constitutively activated in CH27 lymphomas and CpG ODN treatment decreased the 
level of phosphorylated ERK. This suggests that in addition to NFκB, the decrease in c-
myc protein levels might also be regulated by decreasing levels of activated ERK in 
CH27 B cell lymphomas treated with CpG ODN. However, treating CH27 cells with 
inhibitors specific to MAP kinase JNK, ERK or p38 had no significant effect on the 
constitutive proliferation of CH27 cells, and neither restored nor enhanced the inhibitory 
effect of CpG ODN on CH27 cell proliferation.  This suggests that MAP-kinases may not 
 
 96
be essential for constitutive proliferation and CpG ODN-induced apoptosis of CH27 
lymphoma B cells.  
 
This study, using a mouse lymphoma B cell line as a model, demonstrated that CpG 
ODN induces apoptosis in lymphoma B cells that constitutively express c-myc and Bcl-xl 
in a TLR9-dependent manner.  Our study further reveals that TLR9-induced abortive 
activation of NF-κB accompanied by an over-elevated c-myc level is a likely underlying 
mechanism for CpG ODN-induced apoptosis.  Since several common human lymphomas, 
such as B-CLL and Burkitt's lymphoma, have properties similar to CH27 lymphoma B 
cells, it will be extremely interesting to test whether CpG ODN can induce apoptosis in 
these lymphomas by a similar mechanism.  Further studies are required to fully 
understand the mechanism for TLR-induced apoptosis.  
 
TLR9 agonists strongly trigger both innate and adaptive immune responses, making them 
desirable for use as vaccine adjuvants, in cancer and allergy therapy. TLR9 agonists are 
in clinical trials as vaccine adjuvants for cancer and infectious diseases. CpG 7909 is in 
final phase of clinical trials for treatment of non small cell lung cancer. In these clinical 
trials patients undergoing a combination treatment of CpG ODN and monoclonal 
antibody therapy or chemotherapy were shown to have better rates of tumor regression 
and survival. Our data reported here, further supports the use of TLR9 agonists to 







Chapter 3: Polyvalent Antigens Stabilize B Cell Antigen Receptor 





The B cell antigen receptor (BCR) can distinguish subtle differences in antigen structure 
and trigger differential responses.  Here, we analyzed the effects of antigen valency on 
the functions of the BCR using three different antigen systems – anti-BCR antibody –
based antigens, phosphorylcholine (PC)-based antigens and hen egg lysozyme (HEL)-
based antigens.  While both paucivalent and polyvalent antigens induced the 
redistribution of surface BCR into microdomains, polyvalent antigen-induced BCR 
surface microdomains persisted. Significantly, this trend was consistently observed in all 
three antigen systems studied. Ganglioside GM1 and tyrosine-phosphorylated proteins and 
phosphorylated ERK co-localized with BCR microdomains, suggesting these function as 
surface signaling microdomains. Co-receptor, CD19 and MHC class II molecules 
accumulated in the BCR surface microdomains, but CD45 and the transferrin receptor 
were not preferentially concentrated in the microdomains. The cellular distribution of 
microtubule filaments was also influenced by antigen valency. Prolonged BCR caps were 
also concomitant with a reduction in BCR movement to late endosomes/lysosomes. Thus, 
antigen valency influences B cell responses by modulating the stability of BCR-signaling 








B cells express clone-specific receptors, the B cell antigen receptors (BCR), which sense 
the presence of antigens.  B cell responses are initiated by the engagement of antigens to 
the BCR.  The binding of antigens to the BCR initiates signaling cascades, leading to the 
expression of genes involved in cell proliferation and differentiation [245, 246], and 
induces the internalization of antigens for processing and presentation, acquiring T cell 
help [20, 247].  
 
Unlike the T cell antigen receptor, the BCR recognizes antigens in their native forms with 
varying affinity, valency, chemical component and stereochemical structure.  BCR 
engagement can initiate cellular events leading to a wide range of responses, including 
anergy, apoptosis, proliferation, differentiation, or memory B cell generation.  The 
outcome of BCR engagement is influenced by the properties of antigens, differentiation 
stage of B cells, availability of T cell help, and environment of B cells.  In the absence of 
T cell help, a productive B cell response requires thresholds of antigen concentration, 
affinity, and valency [40, 48, 248]. Below these thresholds, MHC class II-restricted T cell 
help is required.  The relationship between antigen affinity and antigen-triggered 
responses has been extensively studied.  Increasing antigen-BCR affinity has been shown 
to enhance B cell antigen presenting ability, T cell-independent B cell proliferation, 
antibody secretion, and interleukin 2 and interferon-γ secretion in vitro [75, 76]. Using 
transgenic mice carrying antibody genes with a high or low antigen binding affinity, Shih 
et al. [72, 74] showed that while high- and low-affinity B cells had the same intrinsic 
capacity to respond to T-dependent antigens, high-affinity B cells generated a two-fold 
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higher response to T cell-independent antigens than low-affinity B cells.  When both 
high- and low-affinity B cells were co-transferred to recipient mice, only high-affinity B 
cells responded to both T cell-dependent and independent antigens [72] and high affinity 
germinal center B cells are actively selected to differentiate into plasma cells [73].  
 
The effect of antigen valency on B cell responses has also been examined.  Increasing 
antigen valency by conjugating BCR-specific antibodies to dextran, Ficoll, Sepharose, or 
polyacrylamide beads reduced the amount of antigens required for induction of B cell 
proliferation [77, 78]. Conversely, increasing antigen valency using biotinylated anti-
BCR antibodies and avidin or by coating anti-BCR antibodies to plastic or erythrocyte 
surface induced abortive activation of B cells and apoptosis [80-82]. Recently, Kim et al., 
reported that oligomeric antigens are more effective than monomeric antigens in inducing 
rearrangement of MHC class II compartments and antigen presentation by B cells [83].  
Antigen valency and affinity also influence the differentiation of B cells into short-lived 
extrafollicular antibody-secreting plasma cells or to enter the germinal center. Decreasing 
antigen valency and affinity results in smaller numbers of antibody-secreting plasma 
cells, but does not affect the germinal center formation [84]. Thus, the property of 
antigens is an important factor that regulates B cell responses.  However, little is known 
about how the BCR distinguishes and interprets differences in the structure and 
configuration of antigens. 
 
The engagement of the BCR by antigens, particularly by multivalent antigens, has been 
shown to induce the reorganization of surface BCR. Early studies [249, 250] showed that 
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antigen cross-linking induced the redistribution of the surface BCRs to polarized caps.  
The formation of BCR caps required multivalent antigens [249, 251]. It has been shown 
that antigen cross-linking induced the association of the BCR with detergent-insoluble 
lipid rafts [252, 253]. Lipid rafts refer to membrane microdomains that are rich in 
cholesterol and glycosphingolipids [254, 255].  The BCR associated with lipid rafts is 
preferentially phosphorylated by Src-family kinases that are either constitutively 
associated or become associated with lipid rafts upon stimulation [19, 20, 22]. 
Downstream signaling molecules, like phospholipase Cγ2, are recruited to lipid rafts 
[256], but phosphatase CD45 is excluded [20].  These data support the model that the 
engagement of the BCR by antigens induces the formation of organized signaling 
microdomains on the B cell surface, and the lipid rafts provide platforms for BCR 
signaling microdomains. Batista et al. [51] provide strong evidence for such a model.  In 
their report, it was demonstrated that BCR engagement by antigens tethered on the 
surface of target cells induced the redistribution of BCR, ganglioside GM1, and tyrosine-
phosphorylated proteins to the contact region between B cells and target cells. Adhesion 
molecules of the antigen tethered cell, like ICAM-1 and VCAM-1 and LFA-1 and VLA-4 
of the B cell are recruited to the microdomains surrounding the BCR [52, 53]. CD45, 
CD22 and SHP-1 were excluded from this region of contact [257]. Such surface 
microdomains are similar to the immunological synapses formed between T cells and 
antigen presenting cells where MHC-restricted interaction is established and regulated 
[57].  However, the mechanisms for the formation of BCR signaling microdomains 
remain to be elucidated, and the factors that regulate BCR signaling microdomains 
remain to be identified.           
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The aim of this study was to investigate the role of antigen valency in regulating the 
cellular functions of BCR. Three different systems of model antigens (Fig. 3-1) and B 
cell models were used. Anti-Ig antibody based antigens were used with F(ab’)2 of anti-
mouse IgM+IgG as a paucivalent antigen and biotinylated F(ab’)2 plus avidin as a 
polyvalent antigen (Fig. 3-1A).  While anti-Ig antibodies have been widely used to 
experimentally induce B cell stimulation, they are not ideal antigens as they presumably 
bind to multiple epitopes on the BCR in contrast to ‘real’ antigen that binds only to the 
amino-terminal antigen-binding site. Therefore, antigens of different valences were also 
generated by conjugating phosphorylcholine (PC) to a carrier protein and hen egg 
lysozyme (HEL) to Ficoll (Fig. 3-1B); and used to study the effects of antigen valency on 
primary splenic B cells of mice expressing Ig transgene that is specific for PC or HEL. 
This work compares, for the first time the effect of these ‘real’ antigens with different 
valences on the formation of BCR surface signaling microdomains, recruitment of 
signaling molecules to these microdomains and intracellular trafficking of the BCR. 
 
Increasing antigen valency is implicated in higher immunogenicity and is deemed a good 
strategy for developing better vaccines [258]. Vaccines that utilize multiple epitopes of 
antigens like viral antigens are more immunogenic requiring fewer booster doses and 
adjuvants. Smallpox, rubella and polio vaccines are examples of these. Hepatitis and 
rabies vaccines that contain monomeric subunits are less efficient in inducing B cell 
responses and require more booster doses [259]. Recent studies have shown that multiple 
repeating epitopes of single protein molecule can increase immune responses. Higher 
valency antigens induce a higher level of IgG antibodies than low valences of the same  
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Figure 3-1. Schematic representation of model antigens used. 
Shown is a representation of (A) BCR-specific antibody based antigens and (B) hen egg 
lysozyme (HEL) based antigens. (A) –XL indicates that surface BCR is labeled with 
fluorochrome tagged Fab fragments of anti-BCR antibody which label the surface BCR, 
but do not cross-link it. +XL and +dXL indicate that the surface BCR is cross-linked by 
paucivalent and polyvalent antigens, respectively. Biotinylated F(ab)’2 fragments of anti-
BCR antibody and Biotinylated F(ab)’2 fragments of anti-BCR antibody followed by 
avidin are termed paucivalent and polyvalent antigens, respectively. (B) Hen egg 
lysozyme (HEL) forms dimers and trimers in solution and is a paucivalent antigen, while 






























































































antigens [260]. However the precise mechanism of the B cell response to varying antigen 
valences still remains unclear. Thus understanding the molecular and cellular responses 
of B cells stimulated with antigens of varying valences will lay the foundation for 






















3.3 Materials and Methods 
Cell lines and mice  
The B cell lymphoma CH27 is an IgM+, H-2k and FcγRIIB1- cell line. These cells express 
surface IgM that has been reported to bind phosphorylcholine [198]. CH27 cells were 
cultured at 37°C in DMEM supplemented as described previously [207] and containing 
15% FBS.  
 
Transgenic mouse strain C207-4, carrying the MOPC-167 (M167) myeloma-derived μ 
plus κ transgene on a BALB/c background [261] was kindly provided by Dr. Michael 
Potter (NCI, NIH, Bethesda). This mouse expressed transgenic BCR specific for 
phosphorylcholine (PC). BALB/c mice were purchased from Charles River Laboratories 
(Frederick, MD). MD4 HEL transgenic mice on C57BL/6 background were provided by 
Dr.Susan Pierce (NIAID, NIH, Rockville). The MD4 mice carry the IghelMD4 transgene 
which recognizes hen egg lysozyme [262].  
 
To obtain splenic B cells, single-cell suspensions of the splenocytes were prepared, and 
then subjected to Ficoll density gradient centrifugation (Sigma, St. Louis, MO) at 2300x 
g for 15 min.  The mononuclear cell fraction was harvested and washed. T cells were 
depleted using anti-Thy 1.2 antibody and guinea pig complement.  The B cells were 
washed and resuspended in medium. Monocytes and dendritic cells were removed by 





Antibodies and reagents 
Thy 1.2-specific monoclonal antibody (mAb) was obtained from BD Pharmingen (San 
Diego, CA).  Guinea-pig complement and Dulbecco’s modified eagle’s medium 
(DMEM) were purchased from Gibco (Grand Island, NY). Hen egg lysozyme (HEL) and 
ovalbumin (OVA) were from Sigma Aldrich (St. Louis, MO). Amino-phenyl phosphoryl 
choline (APPC) and HEL10-Ficoll were purchased from Biosearch Biotechnologies 
(Novato, CA). Aldehyde activated dextran kit was obtained from Pierce Biotechnology 
(Rockford, IL). Cy3-conjugated Fab fragments of goat anti-mouse IgM, biotin-
conjugated F(ab’)2 fragments of goat anti-mouse IgM+IgG and avidin were from Jackson 
ImmunoResearch Laboratories (West Grove, PA). CD45-specific mAb and CD19-
specific mAb were from BD Biotechnology, Inc. (San Diego, CA). 1D4B, a mAb specific 
for lysosomal associated membrane glycoprotein-1 (LAMP-1), anti-I-Ab mouse mAb and 
TIB219, a mAb specific for mouse transferrin receptor (TfR) were obtained from 
hybridomas purchased from ATCC (Rockville, MD). TU-01, a mouse mAb specific for 
the alpha tubulin subunit of microtubules was purchased from Zymed Laboratories Inc. 
(San Francisco, CA). Anti-phosphotyrosine mAb (4G10) was from Upstate 
Biotechnology Inc. (Lake Placid, NY). FITC-conjugated goat anti-mouse IgG2b was 
purchased from Southern Biotechnology Associates Inc. (Birmingham, AL).  Alexa Fluor 







Serotyping M176 transgenic C207-4 litter mates  
To select for mice carrying transgenes of Ig specific for PC, the presence of anti-PC 
antibodies in the serum of M167 Tg mice was detected by ELISA as previously described 
[263]. Blood was collected by tail bleeds, and serum was titrated on PC-BSA coated 
plates. ELISA plates were coated with100 μl of PC-BSA (10 μg/ml) in 50 mM 
carbonate/bicarbonate buffer was added to each microtiter well and left over night at 4°C. 
The plates were blocked with PBS containing 0.1% gelatin for 1 h at 37°C. Serum 
samples were diluted in the same buffer and incubated for 1 h at 37°C. Plates were 
washed three times with a buffer containing 0.01 M Tris, 0.14M NaCl, 0.05% Tween 20 
buffer, pH 7.2. HRP-conjugated goat anti-mouse IgG antibody was added to the wells for 
2 h at 37°C. The plates were washed and developed with 2,2’-Azino-bis-(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) in citrate buffer (pH 4.5) in the presence of 
0.1% hydrogen peroxide. The plates were analyzed with a 96 well plate reader with OD 
at 405nm. The transgenic mice were defined as those animals whose sera had OD reading 
three times higher than wild type controls and litter mates.  
 
Synthesis of PC –based antigens of varying valencies 
Phosphorylcholine (PC) was coupled to HEL and OVA as described by Shaw et al. [264]. 
Aminophenyl phosphorylcholine (APPC) (100 mg) was dissolved in 11 ml of 0.1 N HCl 
at 18 °C. NaNO2 (27.7 mg) was added to the acid/APPC solution to activate APPC to 
form diazophenyl phosphorylcholine (DPPC). To conjugate with proteins like HEL and 
OVA,100 mg HEL or OVA was dissolved in 50 ml borate-buffered saline pH 9.2 (10 
mM borate, 0.15 M NaCl) and DPPC was added gradually and stirred overnight at pH 8.8. 
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The solution was dialyzed against phosphate-buffered saline (PBS) and sterile filtered. 
The protein concentration (HEL or OVA) in the solution was measured by the BCA 
Protein Quantification Kit (Pierce, IL). The number of moles of PC per mole of HEL or 
OVA was measured based on the excitation maximum and molar extinction coefficient of 
DPPC as previously described [265]. The molar extinction coefficient of DPPC at 475 
nm is 12,600 in 0.1 N NaOH. By varying the ratio of DPPC to HEL or OVA in the above 
procedure, we were able to synthesize antigens of varying valencies. We synthesized 
HEL conjugated with 1, 2 or 4 moles of PC and OVA with 1, 3 or 5 moles of PC. PC5-
OVA was also conjugated with dextran using an aldehyde activated dextran kit (Pierce 
Biotechnology, Rockford, IL) using the manufacturer recommended protocol. PC5-OVA-
dextran helped to further increase antigen valency.  
 
Antigen engagement of BCR 
Three different antigen systems were used in this study, including anti-mouse IgM 
antibody-based antigens (Fig.3-1A) , phosphorylcholine (PC)-based antigens and hen egg 
lysozyme (HEL)-based antigens (Fig. 3-1B). Splenic B cells from BALB/c or C57BL/6 
mice or CH27 B cell lymphomas were incubated with 20 μg/ml of biotin-conjugated 
F(ab’)2 fragments of goat anti-mouse IgM+IgG (B-anti-Ig) as a paucivalent antigen (XL). 
For polyvalent antigen cross-linking (dXL), the BCR was incubated with 20 μg/ml of B-
anti-Ig for 10 min followed by 20 μg/ml of avidin for an additional 20 min at 4°C before 
warming. Splenic B cells from M167 mice expressing BCR specific for 
phosphorylcholine, were incubated with 0.1 μg/ml of aminophenylphosphoryl choline 
(APPC) as a monovalent antigen. For polyvalent antigen cross-linking, the BCR was 
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cross-linked with equimolar concentrations of PC in the various conjugates. PC2-HEL 
(2.5 μg/ml)and 1.2 μg/ml of PC4-HEL were used to maintain the PC concentration at 0.3 
nmoles. PC-OVA antigens (PC1, PC3 and PC5) were used at 13.5 μg/ml, 4.5 μg/ml and 3 
μg/ml respectively. Splenic B cells from the MD4 mice which express BCR specific for 
HEL were crosslinked with  6 μg/ml HEL as paucivalent or 22 μg/ml HEL10-Ficoll as 
polyvalent antigens. HEL has been shown to form dimers and trimers in solution [266]. 
All antigens were incubated with the cells for 30 min at 4°C to facilitate binding to the 
BCR, before warming to 37°C. 
 
Immunofluorescence microscopy 
Cells (1 x 106/ml) were incubated with 2.5 μg/ml of Cy3-conjugated Fab fragment of 
goat anti-mouse IgM (Cy3-Fab anti-IgM) to label the surface BCR. After 10 min, cells 
were incubated with model antigens for 30 min at 4°C. Cells were washed with DMEM 
containing 6 mg/ml of BSA (DMEM-BSA) to remove unbound antigen and incubated at 
37°C for varying lengths of time at the end of the incubation. Cells were washed and 
adhered onto poly-L-lysine-coated slides (Sigma, St. Louis, MO) for 40 min at 4°C. Then, 
cells were fixed with 3.7% paraformaldehyde, permeabilized with 0.05% saponin and 
incubated with antibody specific for LAMP-1 (1D4B) or alpha tubulin (TU-01) or 
phosphorylated ERK or phosphorylated JNK and FITC-conjugated secondary antibodies. 
For detection of phosphotyrosine-containing proteins, cells were incubated with anti-
phosphotyrosine mAb (4G10) followed by FITC-conjugated anti-mouse-IgG2b secondary 
antibody. For labeling the surface ganglioside GM1, cells were incubated with AlexaFluor 
488-conjugated cholera toxin B subunit (CTX-B) at 4°C before fixation. For labeling 
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surface molecules like, MHC class II, CD19, CD45 and transferrin receptor (TfR) cells 
were fixed and then incubated with antibodies against I-Ab, CD19, CD45 and TfR 
respectively, followed by appropriate secondary antibodies. Cells were mounted with 
Gel/Mount (Biomeda, Foster City, CA).  Slides were analyzed by laser-scanning confocal 
microscopy (LSM 510, Zeiss) using 100 x oil immersion objective.  The same settings on 
the confocal microscope were used for all conditions of each set of experiments.  Control 
experiments where the primary antibodies were either omitted or substituted by isotype 
control antibodies showed no significant staining signals. 
 
For the quantitative analysis, one hundred cells in five images randomly taken from slides 
of each of three independent experiments were counted for each time point and condition.  
The number of cells containing polarized BCR caps was counted and expressed as a 














Antigen valency and the formation of BCR surface microdomains.                  
Upon cross-linking by antigens, the BCR translocates to lipid rafts where it organizes its 
signaling and endocytosis machinery [20, 253]. To determine the effect of antigen 
valency on the spatial relationship between the BCR and lipid rafts, the cellular 
distribution of the BCR and lipid rafts was analyzed using immunofluorescence 
microscopy. For these studies anti-BCR antibody-based antigens and phosphorylcholine 
(PC)-based antigens were used. To cross-link the surface IgM of splenic B cells from 
BALB/c or C57BL/6 mice using anti-BCR antibody-based antigens, biotin-conjugated 
F(ab’)2 fragments of goat anti-mouse IgM+IgG (B-anti-Ig) were used as a paucivalent 
antigen, and B-anti-Ig plus avidin was used to mimic a polyvalent antigen. To cross-link 
the BCR of splenic B cells from M167 transgenic mice, aminophenyl phosphorylcholine 
(APPC) was used as a monovalent antigen and phosphorylcholine conjugated to 
ovalbumin (PC-OVA) or hen egg lysozyme (PC-HEL) as polyvalent antigens. Cholera 
toxin B subunits (CTX) that bind to glycosphingolipid GM1 with high affinity were used 
to label the lipid rafts.  The surface BCR was labeled with Cy3-conjugated Fab fragment 
of goat anti-mouse IgM antibody (Cy3-Fab anti-IgM) at 4oC in the presence or absence of 
model antigens. As previously shown, B-anti-Ig does not compete with Fab-anti-IgM to 
bind to the BCR [219, 247]. After the chase at 37°C for 60 min, cells were cooled to 4°C 
and incubated with Alexa Fluor-488-CTX without permeabilization to label the surface 
GM1.  In the absence of cross-linking, a portion of the surface labeled BCR moved into 
the cells while some remained on the cell surface, and CTX had a relatively homogenous  
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Figure 3-2. Effect of antigen valency on the cellular distribution of BCR and 
ganglioside GM1   
(A) Splenic B cells from BALB/c mice were incubated with Cy3-Fab anti-IgM alone (-
XL) or in the presence of 20 μg/ml B-anti-Ig (+XL) or 20 μg/ml B-anti-Ig plus 20 μg/ml 
avidin (+dXL) for 40 min at 4°C. (B and C) Splenic B cells from M167 transgenic mice 
were incubated with Cy3-Fab anti-IgM alone (-XL) or in the presence of 0.1 μg/ml APPC 
or 3 μg/ml PC5-OVA or 2 μg/ml PC5-OVA conjugated to dextran (B) or 1.2 μg/ml of 
PC4-HEL (C) for 40 min at 4°C. After incubating at 37°C for 60 min, the cells were 
cooled for 10 min at 4°C, and stained with Alexa Fluor 488-CTX for 40 min at 4°C.  
Cells were then fixed and mounted.  Images were acquired in the middle of the cells 
using a confocal fluorescence microscope.  Bar, 5 μm (C) Shown is a representative 
image of the top view (xz) and side view (xy) of the BCR surface microdomain. On the 
left, is an image of a B cell from M167 transgenic mouse treated with APPC and on the 










































surface staining pattern (Figure 3-2Aa-Ac and 3-2Ba-Bc). Cross-linking the BCR with B-
anti-Ig alone increased the amount of BCR staining in the perinuclear area, but had no 
significant effect on the CTX staining pattern (Figure 3-2Ad-Af and 3-2Bd-Bf).  Treating 
cells with B-anti-Ig and avidin or PC5-OVA or PC5-OVA conjugated to dextran resulted 
in a redistribution of the BCR, forming surface microdomains, while a small portion of 
the BCR was detected inside the cells.  Significantly, in these cells, GM1 staining was 
preferentially co-localized with the BCR (Figure 3-2Ah, 3-2Bh and 3-2Bk).  
The surface BCR redistributed to a polarized, crescent appearance (Figure 3-2Ag) in 
response to BCR cross-linking. Such a polarized distribution of the surface BCR has been 
described as BCR caps [85, 249, 250]. Figure 3-2C shows a top view (xz) and side view 
(xy) of the BCR surface microdomain formed in cells treated with PC4-HEL (Fig. 3-2C, 
right panel) in comparison with a similar view of a cell treated with APPC (Fig. 3-2C, left 
panel). This showed that in B cells treated with PC4-HEL, the surface BCR moved 
together with the GM1 to form a microdomain covering nearly one-third of the cell surface. 
Compared to anti-BCR antibody-based antigens, PC-based antigens induced the 
formation of BCR caps to a lesser extent (Fig. 3-2Bg). The colocalization of CTX as lipid 
raft marker and BCR indicates that both anti-BCR antibody-based and PC-based antigens 
induced the formation of BCR surface microdomains. 
 
Effect of antigen concentration on formation of BCR surface microdomains                  
To test the effect of antigen concentration on the formation of BCR surface microdomain, 
splenic B cells from M167 transgenic mice were treated with varying concentrations of 
PC2-HEL. The cells were incubated with Cy3-Fab anti-IgM at 4°C in the presence of 
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varying concentrations of PC2-HEL and chased at 37°C for varying lengths of time. After 
the chase, the cells were labeled for surface GM1 at 4°C. Using immunofluorescence 
images, the percentage of cells containing polarized BCR surface microdomains was 
quantified. While there was a very slight decrease, there was no significant difference in 
the percentages of cells forming the polarized BCR microdomains with increasing 
antigen concentrations (Figure 3-3). This indicates that optimal concentration of PC2-
HEL antigen lies in the range of 2 – 5 μg/ml of PC2-HEL, which corresponds to about 0.3 
nmoles of PC. PC-based antigens of varying valences were titrated to maintain this molar 
concentration of phosphorylcholine in the following experiments.  
 
Antigen Valency and the Time Course of BCR Surface Microdomain Formation.  
To follow the time course of the surface BCR redistribution, splenic B cells from M167 
and MD4 transgenic mice were incubated with Cy3-Fab anti-IgM at 4°C in the presence 
of corresponding antigens and chased at 37°C for varying lengths of time. After the chase, 
the cells were labeled for surface GM1 (Figure 3-4A and 3-4D).  Before the incubation at 
37°C, the BCR and CTX had a relatively homogenous surface-staining pattern in B cells 
treated either with the paucivalent or polyvalent antigen (Figure 3-4Aa, 3-4Ab, 3-4Da 
and 3-4Db). Upon warming to 37oC, distinct BCR microdomains were detected in few 
cells treated with APPC or HEL after 10 and 30 min incubation at 37oC and a majority of 
the GM1 (Figure 3-4Ac, 3-4Ae, 3-4Dc and 3-4De) staining was co-localized with the BCR. 
By 30 and 60 min the BCR moved from the cell surface to the perinuclear location in  
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Figure 3-3. Formation of surface signaling microdomians in response to varying 
concentrations of antigens. 
Splenic B cells from M167 transgenic mice were incubated with Cy3-Fab anti-IgM alone 
(-XL) or in the presence of varying concentrations of PC2-HEL antigen for 30 min at 4°C, 
warmed up to 37°C for varying lengths of time and cooled for 10 min at 4°C. Cells were 
stained with Alexa Fluor 488 -CTX for 40 min at 4°C. Images were acquired in the 
middle of the cells using a confocal fluorescence microscopy. Bar, 10 μm. Shown is a 
quantitatification of immunofluorescence images generated above. Five images 
containing 100 cells were randomly taken from slides of three independent experiments.  
The number of cells with surface signaling microdomains were counted for each time 
point and condition, and expressed as a percentage of the total number of cells in the 



























Figure 3-4. Time course of formation of BCR surface signaling microdomains.  
Mouse splenic B cells from M167 transgenic mice (A) and MD4 transgenic mice (D) 
were incubated with Cy3-Fab anti-IgM alone (-XL) or in the presence of antigens. Cells 
were incubated with (A) 0.1 μg/ml APPC or 1.2 μg/ml of PC4-HEL or (D) 6 μg/ml of 
HEL or 22 μg/ml of HEL10-Ficoll for 30 min at 4°C. After incubating at 37°C for varying 
lengths of time, the cells were cooled for 10 min at 4°C, and stained with Alexa Fluor 
488 -CTX for 40 min at 4°C.  Cells were then fixed and mounted.  Images were acquired 
in the middle of the cells using a confocal fluorescence microscopy.  Bar, 5 μm. (B, C, E 
and F). Shown are quantitative analyses of immunofluorescence images of percentages of 
B cells from M167 (B and C) or MD4 transgenic mice (E and F) with polarized BCR 
signaling microdomains (B and E) or retaining BCR on the cell surface (C and F). More 
than five images were randomly taken from slides of three independent experiments. The 
number of cells with surface signaling microdomains or surface BCR were counted for 
each time point and condition, and expressed as a percentage of the total number of cells 
in the images. Shown are the averages (± S.D.) of three independent experiments.  
* indicates a statistically significant difference (P<0.05) in percentages of cells with (B 
















































































































































cells treated with APPC or HEL. In cells treated with PC4-HEL or HEL10-Ficoll, the 
surface labeled BCR and GM1 (Figure 3-4Ad and 3Dd) co-clustered to form 
microdomains in the majority of cells as early as 10 min and remained at the surface as 
BCR caps for at least 60 min (Fig. 3-4B and 3-4E).  
 
Using these immunofluorescence images, the percentage of cells containing BCR 
microdomains was quantified (Figure 3-4B and 3-4E).  When treated with APPC only 
20% of cells from M167 trangenic mice showed the formation of surface microdomains 
at 10 min, while 60% of cells treated with PC4-HEL formed the surface BCR 
microdomains. Over the time course tested, more cells treated with PC4-HEL than APPC 
retained these microdmains on the cell surface. While 50% of PC4-HEL-treated cells 
retained the surface microdomains, only 10% of APPC-treated cells retained them after 
60 min of incubation (Figure 3-4B, 3-4C). Similarly, MD4 transgenic mice followed the 
same trend as the M167 transgenic mice. At 60 min of incubation, a higher percentage of 
MD4 Tg B cells treated with HEL10-Ficoll (40%) formed the surface BCR microdomains 
compared to 10% of cells treated with HEL (Figure 3-4E, 3-4F).  
 
Thus, both paucivalent and polyvalent antigens induced the polarized distribution of 
surface BCR and formation of surface BCR cap which co-localized with GM1. However, 
the BCR microdomains induced by the polyvalent antigens persist on the cell surface 
much longer than those induced by the paucivalent antigen. It is significant that this trend 
is consistently observed in different strains of mice and different types of model antigens 
that were tested. The prolonged BCR surface microdomains were not only observed 
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when the anti-BCR antibody-based antigens, which do not necessarily bind the antigen-
binding sites of the BCR, were used, but also with two BCR-specific model antigens that 
bind to the antigen binding site of the BCR.  
 
Antigen Valency and the Recruitment of Signaling Molecules to BCR Surface 
Microdomain.  
To determine whether antigen valency will affect the composition of the BCR surface 
signaling microdomains, we analyzed cellular distribution of signaling molecules in 
response to antigens with different valences. The cellular distribution of BCR co-receptor 
CD19, major histocompatibility complex (MHC) class II, phosphatase CD45, transferrin 
receptor (TfR), microtubules, tyrosine-phosphorylated proteins, phosphorylated 
extracellular signal regulated kinase (pERK), and phosphorylated c-Jun NH2 terminal 
kinase (pJNK) in response to antigens of different valences were followed by 
immunofluorescence microscopy. Splenic B cells from M167 or MD4 transgenic mice or 
CH27 B cells were incubated with Cy3-Fab or FITC-Fab anti-IgM at 4°C to label the 
surface BCR, cross-linked with APPC, PC4-HEL, HEL, HEL10-Ficoll, B-anti-Ig or B-
anti-Ig plus avidin, and chased at 37°C for 45 min. Tyrosine-phosphorylated proteins, 
phospho-ERK, phospho-JNK and microtubules were stained with respective monoclonal 
antibodies after fixation and permeabilization. CD19, MHC class II, CD45 and TfR – 





Figure 3-5. Effect of antigen valency on recruitment of signaling molecules to BCR 
surface signaling microdomains.  
Splenic B cells from M167 transgenic mice (A-C and F), MD4 transgenic mice (G – J) 
and CH27 lymphomas (D, E and K) were incubated with Cy3-Fab or FITC-Fab anti-IgM 
in the presence of model antigens as described in Materials and Methods. After 
incubating at 37°C for 45 min, the cells were cooled for 10 min, and stained with mAbs 
specific for CD19 (A), I-Ab (B), CD45 (C and D), TfR (E), tyrosine phosphorylated 
proteins (F), phospho-ERK (G and H) phosphor-JNK (I and J) or α-tubulin (K) and 
secondary antibodies at 4°C.  Cells were then fixed, mounted, and observed under a 
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CD19 preferentially colocalized with the BCR surface microdomains in cells treated with 
APPC or PC4-HEL (Fig. 3-5A). This colocalization was more prominent in the polarized 
BCR surface microdomains formed in cells treated with PC4-HEL (Figure 3-5Ad-Af). 
MHC class II was evenly distributed on the surface of cells treated with APPC, but 
concentrated in the BCR surface microdomains when treated with PC4-HEL (Figure       
3-5Ba-Bc). In contrast, CD45 (Figure 3-5C and 3-5D) and TfR (Figure 3-5E) staining 
appeared evenly distributed around the cell surface and neither the paucivalent nor 
polyvalent antigens had any significant effect on the surface distribution of CD45 and 
TfR. Significantly, CD45 and TfR did not concentrate in the polarized BCR caps. This 
indicates that the polyvalent antigen-induced BCR surface microdomains preferentially 
recruit CD19 and MHC class II but not CD45 and TfR. 
  
Phosphotyrosine staining colocalized with the BCR in cells treated with APPC or PC4-
HEL (Figure 3-5F). In cells treated with APPC, tyrosine phosphorylated proteins were 
colocalized with BCR on the surface and in the perinuclear location (Fig. 3-5Fa-Fc). PC4-
HEL treated cells showed phosphotyrosine staining mainly on the surface and periphery 
of the cell, colocalizing with the polarized BCR surface microdomains (Figure 3-5Fd-Ff). 
In cells treated with HEL and B-anti Ig as paucivalent antigens, a majority of 
phosphorylated ERK and phosphorylated JNK is cytoplasmic and partially colocalized 
with the BCR in perinuclear location (Fig. 3-5Ga-Gc, 3-5Ha-Hc, 3-5Ia-Ic and 3-5Ja-Jc). 
Cells treated with HEL10-Ficoll and B-anti Ig followed by avidin, showed stronger 
phospho-ERK staining colocalized primarily with the BCR signaling microdomains (Fig. 
3-5Hd-Hf and 3-5Hd-Hf). In contrast, phopsho-JNK staining remains primarily 
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cytoplasmic with few cells showing colocaliztion of phospho-JNK staining with the BCR 
signaling microdomains (Fig. 3-5Id-If and 3-5Jd-Jf), in cells treated with polyvalent 
antigens. The recruitment of tyrosine phosphorylated proteins, active ERK and JNK 
suggests that the BCR surface microdomain formed by polyvalent antigens functions as 
BCR signaling microdomains.  
  
In cells treated with B-anti-Ig alone, the BCR co-localized with the microtubule 
organization center (MTOC) in the perinuclear region (Figure 3-5Ka -Kc). Upon cross-
linking with B-anti-Ig and avidin, which induced the formation of BCR caps, the 
microtubules rearranged to the periphery of the cell and the MTOC was partially 
reoriented to the BCR caps (Figure. 3-5Kd-Kf). This suggests that polyvalent antigens 
altered the organization of microtubules in B cells.  
 
Antigen Valency and the Intracellular Trafficking of the BCR 
To test whether antigen binding influences the kinetics of the movement of the BCR from 
the cell surface to late endosomes/lysosomes, the BCR on the surface of CH27 cells was 
labeled with Cy3-Fab anti-IgM in the presence of anti-BCR-based antigens of different 
valences and chased at 37°C for various times. The cells were labeled with anti-LAMP-1 
antibody to mark the late endosomes/lysosomes. Similar to the results shown in Fig. 3-5A 
and 3-5D, before warming upto 37°C, a relatively homogenous surface-staining pattern 
of the BCR was observed (Fig. 3-6a and 3-6b) in cells either treated with B-anti-Ig alone 
or B-anti-Ig plus avidin. Upon warming to 37°C, the BCR in cells treated with B-anti-Ig 
appeared as punctate staining around the cell periphery (Fig. 3-6c), and then moved into  
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Figure 3-6. Effect of antigen valency on movement of the BCR from cell surface to 
late endosomes/lysosomes  
CH27 cells were incubated with Cy3-Fab anti-IgM in the presence of 20 μg/ml B-anti-Ig 
(+XL) or B-anti-Ig plus avidin (+dXL) for 40 min at 4°C.  Cells were washed and 
incubated at 37°C for varying lengths of time, and then fixed, permeabilized and 
incubated with mAb specific for LAMP-1 (1D4B) and FITC-conjugated goat anti-rat IgG 
secondary antibody.  Images were acquired in the middle of the cells using a confocal 































the cells (Fig. 3-6e). At 60 min, the majority of the BCR clustered in the perinuclear area 
and colocalized with LAMP-1 (Fig. 3-6g). Cross-linking of the BCR with B-anti-Ig and 
avidin resulted in the redistribution of the BCR to polarized caps and significantly 
reduced the colocalization of the BCR with LAMP-1 (Fig. 3-6f, h, j). While BCR caps 
persisted, the colocalization of the BCR with LAMP-1 in these cells increased over time 
(Fig. 3-6 f, h, j).  
 
These data along with Figures 3-5C and 3-5F indicate that cross-linking the BCR with 
paucivalent antigens increases the movement of BCR to late endosomes/lysosomes.  In 
contrast, cross-linking of the BCR with polyvalent antigens reduces the movement of the 
BCR from the cell surface to late endosomes/lysosomes. 
 
Effect of different strains of mice and environment on the formation of BCR surface 
microdomains.  
We have used transgenic mice on BALB/c and C57BL/6 backgrounds in our study. To 
test whether intrinsic differences between the mice affect the ability of the B cells to form 
BCR surface microdomains, we compared the formation of BCR surface microdomains 
between BALB/c and C57BL/6 mice using immunofluorescence microscopy. Cells were 
incubated with Cy3-Fab anti-IgM alone (-XL) to label surface BCR or with B-anti-Ig 
(+XL) or B-anti-Ig followed by avidin (dXL) at 4oC, warmed up to 37°C for varying 
lengths of time and labeled for surface GM1. Using immunofluorescence images the 
percentage of cells containing polarized BCR surface microdomains was quantified. 
When treated with B-anti-Ig, there was no significant difference between the percentages 
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Figure 3-7. Formation of BCR surface signaling microdomians as a function of 
mouse strain and environment. 
(A) Splenic B cells from BALB/c (black bars) and C57BL/6 (grey bars) mice were 
incubated with Cy3-Fab anti-IgM alone (-XL) or in the presence of 20 μg/ml B-anti-Ig 
(+XL) or 20 μg/ml B-anti-Ig plus 20 μg/ml avidin (+dXL) for 40 min at 4°C and then 
warmed up to 37°C for varying lengths of time. (B) Splenic B cells from SPF or 
conventionally housed C207-4 Tg mice were incubated with Cy3-Fab anti-IgM alone (-
XL) or in the presence of 4.5 μg/ml of PC1-HEL, 2.5 μg/ml of PC2-HEL or 1.2 μg/ml of 
PC4-HEL for 30 min at 4°C and then warmed up to 37°C for varying lengths of time. In 
both (A) and (B) the cells were cooled for 10 min at 4°C, and stained with Alexa Fluor 
488 -CTX for 40 min at 4°C. Images were acquired in the middle of the cells using 
confocal fluorescence microscopy. Bar, 10 μm. Shown is a quantitative analysis of cells 
containing surface BCR surface microdomains. Five images were randomly taken from 
slides of three independent experiments.  The number of cells with surface signaling 
microdomains were counted for each time point and condition, and expressed as a 
percentage of the total number of cells in the images.  Shown are the averages (± S.D.) of 















































of splenic B cells from BALB/c and C57BL/6 mice showing the formation of BCR caps 
(Fig. 3-7A). However, when cells were treated with B-anti-Ig plus avidin, the percentages 
of BALB/c splenic B cells with BCR caps was significantly higher than that of C57BL/6 
splenic B cells at all time points (Fig. 3-7A). This suggests that differences between the 
strains of mice affect the ability of B cells to form surface BCR microdomains.  
 
Phosphorylcholine is a ubiquitous chemical present on the cell walls of many 
microorganisms that are found in the environment, like Streptococcus penumoniae [48]. 
M167 transgenic mice spontaneously secrete PC-specific antibodies and the number of 
PC-positive B cells could be affected by the environment that the animals are housed in 
[267]. Hence, we compared the ability of splenic B cells from mice housed in specific 
pathogen free (SPF) and conventional environments to form BCR surface microdomains 
in response to antigens of different valences. Cells were incubated with Cy3-Fab anti-
IgM alone at 4°C (-XL) or in the presence of equimolar concentrations of different 
valences of PC-HEL, warmed up to 37°C for varying lengths of time and labeled for 
surface GM1 at 4°C. Using immunofluorescence images the percentage of cells containing 
polarized BCR surface microdomains was quantified. Similar to results shown in Figure 
3-4B, cross-linking the BCR with PC antigens increased the percentages of cells that 
formed surface BCR microdomains after 10 and 60 min of incubation. However, there 
was no significant difference in the percentages of cells forming surface BCR 
microdomains in B cells from SPF or conventionally housed M167 transgenic mice 
(Figure 3-7B), indicating that B cells from SPF and conventionally housed M167 
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trangenic mice formed BCR microdomains with similar frequency when treated with PC-
























3. 5 Discussion 
Considered together, the results presented here showed that both paucivalent and 
polyvalent antigens induce the formation of BCR surface signaling microdomains. 
Increases in antigen valency prolongs the lifetime of the surface signaling microdomains 
and recruits molecules involved in BCR signaling and antigen presentation to these 
microdomains. Significantly, different model antigen systems and different B cell model 
systems all showed similar results, strongly supporting our conclusion that antigen 
valency influences formation and stability of BCR surface signaling microdomains.  
 
It has long been observed that the binding of polyvalent antigens to the BCR induces the 
reorganization of the surface BCRs into segregated surface domains, called BCR caps 
[249, 250].  However, the significance of BCR caps in B cell activation is not well 
understood. Here we show that cross-linking the BCR with a polyvalent antigen not only 
induced the formation of polarized BCR caps, but also leads to the colocalization of the 
lipid raft marker, CTX, and cellular tyrosine-phosphorylated proteins with the BCR, 
thereby suggesting that BCR caps are signaling microdomains on the B cell surface. Our 
time course study following the cellular distribution of surface labeled BCR showed that 
BCR caps were formed within 10 min in cells treated with both paucivalent and 
polyvalent antigens.  When treated with paucivalent antigens, the number of cells 
containing BCR caps decreased as BCR internalization increased with time. The BCR 
moved into the cells more slowly and the BCR signaling microdomains persisted for a 
longer time in cells treated with polyvalent antigens. The surface signaling microdomains 
induced by antigens with relatively low valences were transient followed by BCR 
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internalization, while antigens with high valences stabilized the BCR signaling 
microdomains. The relationship between antigen valency and the lifetime of BCR 
signaling microdomains implies that modulating the stability of the BCR signaling 
microdomains is a mechanism by which antigens regulate BCR functions.   
 
Antigen-induced BCR clusters that we report here appear to be similar to BCR synapses 
described by Batista et al. [51, 257].  Their study showed that B cell interaction with 
antigens attached to a target cell surface led to the concentration of the surface BCR in 
the contact region between the B cell and the target cell.  The BCR along with CTX, 
tyrosine phosphorylated proteins, actin filaments and phospholipase Cγ2 were found to 
accumulate in the region of the synapse, while the phosphatases SHP1 and CD45 were 
specifically excluded.  Similarly, our data show that polyvalent antigens induced co-
clustering of the BCR, CTX and tyrosine-phosphorylated proteins but not CD45. We also 
observed co-localization of CD19, MHC class II and phosphorylated ERK in the surface 
microdomains, indicating that these surface microdomains likely function as BCR 
signaling microdomains. 
 
Different from the immunological synapses reported previously, the surface BCR clusters 
reported here are induced by soluble polyvalent antigens, but not antigens tethered on the 
cell surface.  This extends the previous studies by demonstrating that soluble polyvalent 
antigens can induce the formation of stable surface signaling microdomains similar to the 
immunological synapses.  However, the surface signaling microdomains induced by 
soluble antigens may be different from those formed in the contact region between two 
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cells, considering the ability of the BCR to distinguish antigens of different forms.  
Indeed, we found that unlike the synapses formed in the cell-cell contact regions where 
CD45 is excluded, CD45 was neither preferentially concentrated in nor excluded from 
the polarized BCR caps induced by soluble antigens.  Further studies are required to 
characterize BCR signaling microdomains induced by soluble antigens and compare them 
with those induced by antigens tethered on the cell surface. 
 
Three different model antigen systems, including anti-BCR antibody-, 
phosphorylcholine- and hen egg lysozyme-based antigens, were used in this study. The 
antigens were designed and synthesized to change the number of BCR binding epitopes 
without altering the affinity and concentration. While anti-BCR antibodies have been 
widely used as surrogate antigens to induce B cell stimulation, they are not ideal model 
antigens as they presumably bind to multiple epitopes on the BCR in contrast to ‘real’ 
antigen that binds only to the amino-terminal antigen-binding site. Because they bind to 
different regions, it is possible that conformational changes that accompany antigen 
binding to the BCR are not replicated by cross-linking the BCR with anti-BCR antibodies. 
In addition to anti-BCR antibody-based antigens, in this study we have used PC- and 
HEL-based antigens to activate transgenic B cells that express BCR specific for PC and 
HEL. Phosphorylcholine is a ubiquitous chemical group found on the surface of Gram 
positive and lipopolysaccharide (LPS) of some Gram negative bacteria. For example, PC 
is expressed on the cell wall of Streptococcus pneumoniae [268]. The M167 transgenic 
strain of mice carries VH1/Vκ24 gene segments of the myeloma protein MOPC-167 
[261] and express BCR specific for phosphorylcholine [263]. The murine B cell 
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lymphoma CH27 has also been shown to bind synthetic phosphatidylcholine-containing 
lipid vesicles [198]. MD4 HEL transgenic mice express heavy and κ light chains specific 
for hen egg lysozyme [262]. Similar to anti-BCR-based antigens, both PC-based and 
HEL-based antigens induced the formation of stable BCR surface microdomains which 
colocalized with ganglioside GM1 and tyrosine phosphorylated proteins, and increases in 
valency  of PC- and HEL-based antigens increased the stability of BCR surface 
microdomains, validating their use as model antigen systems.  
 
It should be noted that the transgenic mice used are on two different genetic backgrounds 
and could influence the reproducibility of these data. We compared the levels of BCR 
surface signaling microdomains formed in B cells from BALB/c and C57BL/6 strains 
using anti-BCR antibody-based antigens. We found that there were higher percentages of 
B cells from BALB/c mice than C57BL/6 mice forming curface BCR caps in response to 
polyvalent antigens. Previous studies of capping response of B lymphocytes from 
different strains of mouse showed quantitative and kinetic differences in BCR cap 
formation [269] and the genetic differences between strains of mice have been speculated 
to give rise to such differences. Thus the differences between BALB/c and C57BL/6 mice 
should be considered when interpreting data from the different transgenic mice. 
   
Our previous report showed that increases in antigen valency, which increased BCR 
residency in the surface signaling microdomains, enhanced the overall level and duration 
of protein tyrosine phosphorylation [85]. Here, we showed that CD19 co-localized with 
the BCR in signaling microdomains in cells treated with both paucivalent and polyvalent 
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antigens. However, this co-localization was more prominent in cells treated with 
polyvalent antigens. CD19/CD21 is a co-receptor complex that synergistically enhances 
BCR signaling by decreasing signaling threshold [270]. Recruitment of CD19 to the BCR 
signaling microdomains could be the underlying mechanism for enhanced signaling 
induced by polyvalent antigens. Furthermore, polyvalent antigens, but not paucivalent 
antigens induced the redistribution of surface MHC class II to co-localize with the BCR 
signaling microdomains. The biological significance of the recruitment of MHC class II 
to the BCR signaling microdomains remains to be elucidated. MHC class II has been 
shown to be preferentially located in the lipid rafts [271] and can transduce signals 
through Igα upon engagement by TCR [272]. Recruitment of MHC class II to BCR 
signaling microdomains may provide it an opportunity to interact with Igα and to 
contribute to BCR-mediated signaling. In addition, recruitment of MHC class II to BCR 
surface signaling microdomains could be a mechanism for the interaction of BCR 
signaling pathway with it’s antigen processing pathway. ERK and JNK are downstream 
MAP kinases of BCR signaling cascade. Syk and BLNK activate ERK through the 
Ras/Raf/MEK pathway [273], and JNK through Vav and Rac [274]. The MAP kinases 
phosphorylate and activate different sets of transcription factors including, Elk-1 and c-
myc by ERK and c-Jun and ATF-2 by JNK. Phosphorylated, active form of ERK was 
also seen to co-cluster with the BCR in the surface signaling microdomain induced by 
polyvalent antigens, further enhancing signaling from the microdomains. However, there 
is partial co-localization of phosphorylated JNK with the BCR microdomains, indicating 
that ERK and JNK are differentially regulated in the B cells. This also reflects on the role 
of JNK is a stress-activated protein kinase, the activation of which has been implicated 
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during BCR-mediated apoptosis [275]. In contrast, CD45 was not concentrated in the 
BCR signaling microdomains induced by polyvalent antigens. CD45 is a receptor 
phosphatase that can dephosphorylate inhibitory tyrosine phosphorylation sites of Src-
kinases in the early stage of BCR signaling [276] and dephosphorylate the active Src-
kinases and dampen later stages of BCR signaling [20]. The lack of co-clustering of 
CD45 with the BCR signaling microdomains could delay the downregulation of signaling 
from the BCR surface microdomains. Thus, increases in antigen valency could enhance 
BCR signaling by increasing stability of BCR surface signaling microdomains and by 
recruiting BCR co-receptor CD19, and BCR signaling molecules, like phosphorylated 
ERK, but not signaling downregulators lke CD45. This provides a novel explanation for 
why high valent antigens are generally more immunogenic. 
 
How antigens regulate the stability of BCR signaling microdomains remains to be 
elucidated.  We have previously reported that the increase in BCR residency in the 
surface signaling microdomains and BCR-triggered protein phosphorylation was 
associated with a decrease in BCR internalization [85].  This is consistent with our earlier 
observation that an inhibition of BCR internalization slowed down the attenuation of 
BCR-triggered protein tyrosine phosphorylation [219].  Here, we further showed that 
increases in antigen valency slowed down the movement of BCR from the cell surface to 
late endosome/lysosomes. These results suggest that inhibition of internalization is one of 
the mechanisms for stabilizing surface signaling microdomains. This reduced 
internalization is probably the result of large sizes of antigens, which become 
unmanageable for the endocytosis machinery.  Additionally, the actin cytoskeleton that 
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has been shown to accumulate under BCR caps [277] could prevent the endocytosis 
machinery proteins from entering the signaling microdomains or inhibit membrane 
deformation required for endocytosis. Hence we observed that microtubules were 
partially reoriented to the BCR signaling microdomains or redistributed to the periphery 
of the cell in cells treated with polyvalent antigens. The accumulation of microtubules 
could also influence the internalization rate of the BCR and its movement from cell 
surface to late endosome/lysosomes.  
 
In addition to internalization, the stability of BCR signaling microdomains is likely to be 
regulated by multiple interrelated factors. CD19 co-receptor was concentrated in the BCR 
signaling microdomains in cells treated with polyvalent antigens. Co-ligation of CD19 
and BCR has been reported to prolong the residency of BCR in rafts [266], suggesting 
that interaction between BCR and CD19 in lipid rafts can contribute to the stability of the 
BCR surface microdomains. Syk has been shown to play a role in the formation of tightly 
capped BCR complexes on the cell surface [278], probably by regulating the assembly of 
actin filaments.  Pure and Tardelli [78] reported that capping of the BCR in cells treated 
with the tyrosine kinase inhibitors genistein or tyrphostin was incomplete and retarded, 
which suggests a positive feedback from BCR-initiated signaling to BCR capping.  
Therefore, the recruitment of co-receptors and signaling component to the signaling 
microdomains and reorganization of the cytoskeleton could all influence the stability of 




The findings presented here may help to explain how the BCR distinguishes antigens 
with different properties, particularly structural differences.  A major characteristic of T 
cell-independent type-2 (TI-2) antigens is their multiple, repeating antigenic determinants.  
TI-2 antigens include the outer membrane molecules displayed on the surface of 
microbial pathogens, such as antigens displayed on the surface of Neisseria meningitis 
and influenza that cause severe diseases [48].  B cell responses to TI-2 antigens are 
essential for immune protection against microbial pathogens.  Self-antigens, like double 
stranded DNA, actin filaments, collagens and cell surface molecules, are often presented 
in polyvalent forms.  Unresponsiveness of B cells to self-antigens is critical for immune 
tolerance.  TI-2 antigens need to activate B cells in the absence of T cell help.  Without 
signals provided by T cells, signaling initiated by the interaction of antigens and the BCR 
probably becomes the major driving force for B cell activation, and B cell responses to 
TI-2 antigens are likely to be sensitive to the magnitude and duration of the signaling 
events.  The binding of polyvalent antigens stabilizes the surface signaling microdomains 
and recruits signaling molecules, like CD19 and ERK which provides a way to enhance 
BCR signaling and ensure B cell activation in the absence of T cell help.  Besides BCR-
initiated signaling and signals provided by T helper cells, additional signals provided by 
T cell-independent sources, such as Toll-like receptors and complement receptor CD21, 
are important for the outcome of antigen-BCR interaction [45, 48].  These additional 
signals can be triggered by surface molecules of microbial pathogens, DNA and 
complement factors associated with pathogens.  In the absence of additional signals from 
either T cells or T cell-independent sources, extensive cross-linking of the BCR by 
polyvalent antigens has been shown to induce apoptosis [80, 81], which maintains the 
 
 151
self-tolerance of B cell responses.  The relationship between the stability of B cell surface 
signaling microdomains and the fate of B cells remains to be examined.  We can predict 
that both antigen structural properties and co-stimulatory signals regulate the stability and 
composition of BCR surface signaling microdomains, which influence the fate of B cells.  
Future studies should focus on detailing the differences in the composition of BCR 
surface signaling microdomains induced by antigens with different valences and cellular 



































Chapter 4: General Conclusions and Future Experiments 
 
4.1 Differential responses of primary B lymphocytes and B lymphoma cells to TLR9 
ligand 
Conclusions 
The mammalian innate immune system recognizes conserved molecular patterns among 
microorganisms through the family of Toll-like Receptors (TLRs) [5]. Activation of the 
TLRs leads to induction of inflammatory responses and facilitates antigen-specific 
adaptive immunity [199]. TLR-9 recognizes DNA oligonucleotides (ODNs) containing 
unmethylated cytosyl guanosyl (CpG) sequences. The expression of TLR9 in humans is 
restricted to plasmacytoid dendritic cells and B cells [201]. TLR9 is differentially 
expressed and activated in subsets of B lymphocytes. Memroy B cells and transformed B 
cell lymphomas vary in their responses to CpG ODN compared to naïve splenic B cells. 
The work described in this dissertation characterized, for the first time, a potential 
mechanism for the differential responses of lymphoma B cells and primary splenic B 
cells to TLR9 ligand, CpG ODN.  
 
In this dissertation, I have compared the differential effects of CpG ODN on mature 
splenic B cells and a B lymphoma cell line. Our studies show that CpG ODN induces 
proliferation of splenic B cells but leads to apoptosis of CH27 murine B lymphoma cell 
line. The apoptotic and proliferative effect of CpG ODN depends on the presence of the 
CpG motif. CpG ODN-induced apoptosis is mediated by TLR9 as a clonal variant of the 
B cell lymphoma line which does not express tlr9 mRNA is unresponsive to CpG ODN. 
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This indicates that CpG ODN-induced apoptosis is a sequence-specific, TLR9 mediated 
event. Apoptosis in CH27 lymphomas was characterized by increased levels of cleaved 
caspase-3 and decrease of Bcl-xl, an anti-apoptotic protein.  
 
TLR9 signaling leads to activation of NF-κB [146, 168]. CH27 B cell lymphoma line 
shows transient activation of NF-κB and degradation of IκBα, in response to treatment 
with CpG ODN. In sharp contrast, splenic B cells treated with CpG ODN exhibited 
sustained activation of NF-κB and degradation of IκBα. NF-κB inhibitor reduced the 
CpG-induced proliferation of splenic B cells and exacerbated the CpG-induced reduction 
in proliferation of CH27 lymphomas. These data indicate that CpG ODN-induced 
deregulation of NF-κB activation is a likely mechanism of apoptosis in the CH27 
lymphoma cells. c-myc is constitutively expressed at high levels in CH27 B cell 
lymphomas. Treatment with CpG ODN leads to a further increase in c-myc protein levels 
followed by decrease to below constitutive levels in the B lymphoma cells while CpG 
ODN induced sustained increase in protein levels of c-myc in splenic B cells. Inhibitors 
specific for the MAP kinases, JNK, ERK and p38 did not affect the inhibitory effect of 
CpG ODN on CH27 cell proliferation, suggesting that MAP-kinases may not be involved 
in CpG ODN-induced apoptosis of CH27 lymphoma B cells. Taken together, these data 
indicate imbalanced activation of NF-κB and c-myc in the lymphoma B cells is a 
potential mechanism that leads to CpG-induced apoptosis. 
 
The data presented here showed that CpG-induced apoptosis of CH27 B lymphoma cells 
occurs by deregulated NF-κB activation and c-myc and Bcl-xl expression. CpG ODN 
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induces proliferation of primary B cells in culture by sustained activation of NF-κB and 
by upregulating expression levels of c-myc and Bcl-xl. In contrast, CpG ODN induced 
apoptosis in lymphoma B cells due to an abortive activation of NF-κB, which could lead 
to the down-regulation of pro-proliferation genes like c-myc and anti-apoptotic genes like 
Bcl-xl. It was found that decrease in NF-κB activity was concurrent with an over-
elevated c-myc level in CpG ODN-treated CH27 lymphoma B cells. Imbalance between 
the decreasing activity of NF-κB and high levels of c-myc could generate a situation, 
where cell proliferation induced by c-myc in the absence of sufficient anti-apoptotic 
signals from NF-κB, culminates in apoptosis. Therefore, CpG ODN-induced imbalance 
between c-myc and NF-κB is a likely underlying mechanism for CpG ODN-induced 
apoptosis.   
 
Our data and previous studies suggest a potential therapeutic value for CpG DNA in 
cancer treatment. Cancers are treated based on the type, location and progression of the 
tumor. Traditional cancer therapies including radiation therapy and chemotherapy kill, 
shrink or block proliferation of tumor cells and have deleterious side effects on normal 
bystander cells. Further these treatments do not eliminate tumors completely resulting 
disease recurrence. Activating the host immune system can result in targeted deletion of 
tumor cells and holds great promise for cancer therapy. TLR9 agonist, CpG ODN has 
demonstrated potent antitumor activity in mouse models and human clinical phase trials.  
 
Tumors can be treated with CpG ODN as monotherapeutic, as adjuvant in tumor vaccines 
or in combination with monoclonal antibodies or chemotherapy. Monotherapy of cervical 
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carcinoma and T lymphoma with CpG ODN show tumor regression in a T cell or NK 
cell-dependent manner [204]. TLR9 expressing cancer cells like malignant B cell chronic 
lymphocytic leukemias (B-CLLs) are sensitized to monoclonal antibody therapy without 
increasing toxicity to normal cells when treated with CpG ODN [279]. While there is a 
lot of enthusiasm for the use of vaccines against solid tumors it has translated into little 
success in clinical trials [280]. Induction of cytotoxic CD8+ T lymphocytes (CTL) which 
can directly kill tumor cells is the goal of cancer vaccines. This depends on the activation 
of these cells through their interactions with CD4+ T cells and antigen presenting cells 
like dendritic cells. Toll-like receptor agonists, TLR9 agonists in particular are promising 
candidates that can enhance the T cell response of cancer vaccines [281]. As adjuvant in 
cancer vaccines, CpG ODN can stimulate tumor-infiltrating plasmacytoid dendritic cells 
(pDCs) creating a Th-1 like cytokine and chemokine milieu. The activated pDCs up-
regulate co-stimulatory molecules and present tumor antigens to CD4+ T cells which can 
activate CTLs. CpG ODN in combination with tumor vaccines has been shown to be 
more effective in eradicating established tumors in mice [282]. Monoclonal antibody-
based therapy is the fastest growing class of cancer therapy. Rituximab or Rituxan, an 
anti-CD20 monoclonal antibody has demonstrated efficacy in treating patients with 
various forms of lymphoid malignancies [283]. CpG ODN in combination with 
Rituximab monoclonal antibody enhances antibody mediated cytolysis of tumors [284] 
and with chemotherapy reduces suppressive effects of T regulatory cells, enhancing T 




Our study further supports the use of CpG ODN in cancer treatment. The remarkable 
differential responses of primary B cells and B lymphoma cells to treatment with CpG 
ODN further indicates that CpG ODN can be used to eradicate TLR9 expressing cancer 
cells without toxicity to normal cells. CpG 7909 (also known as CpG 2006) has been 
administered to more than 400 patients in human clinical trials for lung cancer and 
melanoma [126]. As yet, there has been no report of organ cytotoxicity in these patients. 
Our data provides further evidence that targeted activation of TLR9 by CpG ODN in 
cancer cells that express TLR9 can tremendously enhance cancer treatment without 
harming normal cells.  
 
Activation-induced cell death mediated by TLRs has been described a number of times 
and seems to be an evolutionarily conserved mechanism. Plant disease resistance genes, 
R genes, have LRRs and TIR domains and share homology with the TLR [286]. These 
genes initiate a hypersensitive response characterized by localized cell death, which is 
similar to apoptotic death, and helps limit the spread of microbes [287]. In mammalian 
cells, bacterial lipoproteins signaling through TLR2, LPS through TLR4, and dsRNA 
through TLR3 and CpG DNA through TLR9 have been shown to induce apoptosis 
especially in stimulated cells [185, 191, 196, 202]. While immunostimulatory functions 
of TLRs are well characterized, the mechanism and relevance of TLR-mediated apoptosis 
remains unclear. However, it can be speculated that apoptosis of activated cells serves to 
limit their lifespan and control the duration of the inflammatory response [186]. This is 
probably a crucial feedback mechanism, to prevent an overactive inflammatory response 
that could lead to autoimmune diseases and disease pathologies like sepsis and airway 
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inflammation [203]. Thus, the TLR9-mediated apoptotic pathway described in this 
dissertation can be speculated to be a physiologically relevant mechanism by which the 
mammalian host controls inflammation and induces an effective immune response.  
 
Future Experiments 
TLR9-induced cell death has been previously reported, however the underlying 
mechanism of this phenomenon has not been well characterized. We have described here 
a CpG-sequence specific, TLR9-mediated onset of apoptosis in a B lymphoma cell line. 
To further understand TLR9-induced apoptosis, as future work we will determine, which 
apoptotic pathway is activated in the cells activated by TLR9 ligand. Our data indicates 
that caspase-3 is involved in this response. Caspase-3 can be activated by caspase-8 or 
caspase-9. Caspase-8 mediates apoptosis signaling from the death receptor family 
(extrinsic apoptosis pathway) while caspase-9 is activated by release of cytochrome c 
from mitochondria (mitochondrial apoptosis pathway). Following the activation of these 
two caspases by Western blots and flow cytometry, will allow us to test whether the 
extrinsic or mitochondrial pathway is responsible for TLR9-induced apoptosis. If the 
extrinsic pathway is implicated in TLR9-induced apoptosis, we should next determine 
whether CpG ODN regulates the expression of death receptors and their ligands, like Fas, 
Fas ligand, TRAIL receptors, TRAIL, on the lymphoma B cells in comparison to splenic 
primary B cells. Further, we should test the functional involvement of FAS and TRAIL 
receptor using antibodies that are able to block ligand binding. In addition, we need to 
examine whether CpG ODN regulates the expression and activation of other Bcl-2 family 




MyD88, the primary adaptor molecule in TLR9 signaling pathway, contains a death 
domain (DD). In cells undergoing apoptosis through TLR2, MyD88 has been shown to 
bind Fas associated death domain protein (FADD) via DD-DD interactions [186], which 
activates caspase-8 leading to apoptosis. Recent studies have also implicated a role for 
FADD in TLR-induced proliferation of B cells. B cells from FADD-deficient mice do not 
undergo proliferation in response to stimulation with TLR3 and TLR4 ligands [288]. This 
suggests that FADD is involved in TLR signaling in B cells. The dual role of FADD in 
TLR-induced apoptosis and proliferation in B cells makes it an interesting candidate for 
further study. It will be interesting to test whether FADD is involved in CpG ODN-
induced apoptosis in CH27 B lymphomas, using CH27 cells that are deficient in FADD. 
We can transfect dominant negative constructs of FADD into CH27 cells and test the 
response of these cells to CpG ODN. We can further compare the kinetics and levels of 
activation of FADD in the splenic B cells and CH27 B lymphoma cell. This will yield 
clues about possible differences in the TLR signaling pathway that leads to proliferation 
or apoptosis in the two types of B cells. 
 
CpG ODN-induced apoptosis suggests a therapeutic effect of CpG ODN on cancers that 
express TLR9. To further test the therapeutic potential, we should test the effect of CpG 
ODN on human B cell lymphomas and patient biopsies of B cell lymphomas. From 
published studies, it is evident that TLR-induced apoptosis differs based on apoptotic 
machinery available and cytogenetic status of the cells [186, 195, 196]. B cell lymphomas 
are characterized into various types based on molecular alterations and only certain types 
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of B cell lymphomas are likely to respond to CpG ODN. Molecular profiling of patient 
biopsy samples of lymphomas that respond to CpG ODN will help to narrow the likely 























4.2 Effect of antigen valency on BCR functions 
Conclusions 
Humoral immune responses are initiated by antigen binding to the B cell antigen receptor 
(BCR). Binding of antigen to the BCR triggers a signaling cascade and initiates the 
internalization of the BCR-antigen complex. B cells are exposed to myriad antigens of 
varying affinity, size, valency, concentration, stereochemical structure and density of 
antigenic epitopes. The quality and quantity of immune responses mounted by B cells are 
modulated by these inherent properties of antigens. However, little is known about how 
the BCR distinguishes and interprets differences in the structure and configuration of 
antigens. The goal of this study was to investigate the role of antigen valency in 
regulating the function of BCR 
 
In this dissertation, three different model systems of antigens and B cells were used to 
study the effects of antigen valency on BCR functions. Anti-BCR antibody based 
antigens, phosphorylcholine-based antigens and hen egg lysozyme-based antigens. Anti-
BCR antibodies have been extensively used to induce B cell stimulation; however they 
are not ideal antigens as they presumably bind to multiple epitopes on the BCR in 
contrast to ‘real’ antigen that binds only to the amino-terminal antigen-binding site. 
Therefore, phosphorylcholine (PC)-based and hen egg lysozyme (HEL)-based antigens 
were used, which bind specifically to the antigen binding site of BCR of mice carrying Ig 
transgene specific for PC and HEL. Significantly, all three model systems of antigens and 
cells influenced BCR functions in a similar manner. 
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Antigen binding to the BCR induces a translocation of the BCR to lipid rafts where it 
initiates signaling cascades and organizes its endocytosis machinery that leads to the 
internalization of the BCR-antigen complex for antigen processing and presentation to T 
cells. My studies show that stimulating the BCR with both paucivalent and polyvalent 
antigens led to rearrangement of the BCR into polarized surface microdomains which co-
localized with the lipid raft marker, ganglioside GM1 and tyrosine-phosphorylated 
proteins, suggesting that these microdomains possibly function as signaling 
microdomains on the B cell surface. Surface signaling microdomains that are induced by 
polyvalent antigens persisted longer on the B cell surface than those induced by 
paucivalent antigens. This was also accompanied by a decrease in movement of the BCR 
to LAMP-1 positive late endosomal/lysosomal compartments. Thus antigen valency 
influences the formation and stability of the BCR surface signaling microdomains.  
 
Our previous published study has shown polyvalent antigens enhance the level and 
duration of protein tyrosine phsphorylation [85]. In the present study, we observed that 
polyvalent antigens induced the concentration of signaling molecules like, CD19, MHC 
class II and phosphorylated form of MAP kinases, ERK and JNK in BCR signaling 
microdomains but not signaling down regulators like, CD45 or transferrin receptor. Thus, 
polyvalent antigen-induced formation of stable BCR surface signaling microdomains 
leads to recruitment of signaling molecules like, CD19 and phosphorylated ERK and 
JNK which enhance signaling from the BCR surface microdomains. We further propose 
that enhanced signaling from BCR microdomains could act as a positive feedback loop, 
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leading to the recruitment of proteins like the cytoskeletal proteins and 
CD19/CD21/CD81 complex, which further stabilize the microdomains.  
 
Based on data presented here and previous studies [85], we propose that antigen valency 
influences BCR functions by regulating the formation and stability of BCR surface 
signaling microdomains and differentially recruiting signaling molecules to the 
microdomains. Paucivalent antigens cross-link the BCR and initiate signaling and 
internalization of the BCR. The BCR-antigen complex is internalized much more rapidly 
in cells treated with these antigens compared to cells treated with antigens that do not 
cross-link the BCR. The antigen-induced signaling from the BCR activates the 
transcription of genes that control B cell responses. Enhanced internalization of the BCR-
antigen complexes leads to effective processing and presentation of antigens to T cells, 
which is essential for induction of T cell- dependent B cell responses. Polyvalent antigens 
form stable BCR signaling microdomains in lipid rafts and enhance signaling but lead to 
a reduction in internalization of the BCR-antigen complexes. The enhanced signaling 
from polyvalent antigen-induced BCR microdomains could elicit a B cell response, even 
in the absence of T cell help. Reduction in internalization and movement of the BCR-
antigen complex limits the availability of T cell help. T-independent signals in the form 
of Toll-like receptors and complement receptors probably have a significant influence on 
the cellular responses of the cells exposed to polyvalent antigens. Thus we propose that 
antigen valency regulates the formation and stability of BCR surface signaling 
microdomains which influences cellular responses of the B cell.  
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Rational design of immunogens that are capable of eliciting protective immunity is a 
challenge in developing potent vaccines. Many variables of the antigen like valency nad 
orientation affect the immunogenicity of vaccines. While there is evidence that increasing 
antigen density or valency results in enhanced humoral responses, few attempts have 
been made to compare the how antigen specific B cells distinguish and respond to 
antigens of varying valences. Efficacy of conjugate vaccines like Hemophilus influenza B 
(Hib) vaccine which consist of purified capsular polysaccharide covalently linked to 
carrier protein are affected by length of polysaccharide chain and density of carbohydrate 
hapten [289]. Studies in monkeys and humans have shown that antibody titer increased 
with the number of repeating carbohydrate units [290, 291]. Zinkernagel and colleagues 
have shown the close correlation between epitope density and B cell responses in viral 
infections [292]. Recent studies have shown that multiple repeating epitopes of single 
protein molecule can increase immune responses [293]. Thus the work on the effect of 
antigen valency on BCR functions described in this dissertation seeks to define the effect 
of antigen valency on BCR functions. The data indicates that increasing antigen valency 
enhances and prolongs BCR signaling while reducing the internalization and trafficking 
of the BCR from cell surface, supporting the theory that increasing antigen valences can 
be an effective tool to develop vaccines with better efficacy. 
 
Future Experiments 
Upon antigen binding, the BCR translocates to lipid rafts, where it organizes signaling 
and endocytosis machinery and initiates signaling cascades and transport of antigen into 
the cell for processing and presentation. Our studies indicate that antigen properties 
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influence the formation and stability of BCR surface signaling microdomains. Future 
studies should focus on the underlying mechanism of the regulatory role of antigen 
valency on BCR functions and its relationship with antigen immunogenicity. To 
understand how antigen valency regulates BCR function, I would like to determine the 
effect of antigen valency on the composition of the BCR microdomains and the kinetics 
of recruitment of different molecules. Upon antigen binding, the BCR translocates to 
lipid rafts and signaling is initiated by Src family kinases like Lyn, Fyn, Blk. Signaling is 
further amplified by kinases, Syk and Btk [35]. Immunofluorescence microscopy can be 
used to study the effect of antigen valency on the recruitment of Src kinases, Syk and Btk 
to BCR signaling microdomains. Cellular responses of the B cells are influenced by the 
activation of MAP kinases and transcription factors. Hence it will be interesting to see the 
effect of antigen valency on total cellular phosphorylation levels, the phosphorylation of 
MAP kinases - JNK, p38 and ERK, and activation of transcription factors like NF-κB, 
AP-1, ATF, and c-myc. Antigen binding to the BCR also stimulates the internalization 
and trafficking of the BCR-antigen complexes for processing and presentation to T cell. 
Our data showed that polyvalent antigens cause a reduction in internalization of the BCR 
and movement to late endosomal/lysosomal compartments. This suggests that the 
endocytosis machinery proteins like clathrin, dynamin and AP-2 are regulated 
differentially when antigens of varying valences bind to the BCR. I would like to test the 
effect of antigen valency on the recruitment of clathrin, dynamin, AP-2 and the 
phosphorylation of clathrin. Further, it is speculated that the ITAMs of the Igα/Igβ 
heterodimers contain motifs that influence the internalization of the BCR [294]. Recent 
fluorescence resonance energy transfer (FRET) studies [19, 22] indicate that antigen 
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binding leads to conformational changes of the Igα/Igβ heterodimer. It can be 
hypothesized that antigens of different valences could induce different conformational 
changes in the Igα/Igβ heterodimer influencing the access of signaling molecules and 
endocytosis machinery proteins to the BCR. It will be interesting to test this with 
immunofluorescence microscopy and FRET studies. Upon antigen binding, the B cell 
mounts diverse cellular responses including, proliferation, cytokine secretion, 
differentiation to antibody secreting plasma cells, anergy or apoptosis. Studies have 
implicated that antigen valency influences the cellular responses [77, 80] of B cells. I 
would propose to test the effect of antigen valency on B cell responses in vitro and in 
vivo.  In vitro studies will be carried out to examine the effect of antigen valency on 
proliferation of B cells, Ig and cytokine secretion and efficiency of antigen processing 
and presentation in B cells. In vivo experiments will monitor titers of antibody and 
generation of memory B cells in mice immunized with antigens of varying valences.  It 
will be of significant interest to correlate the molecular signaling events to the cellular 
responses of proliferation, antigen processing and presentation, antibody secretion and 
memory B cell generation using a system of physiologically relevant antigens. Increasing 
antigen valency is implicated in higher immunogenicity and is deemed a good strategy 
for developing better vaccines [258]. Thus, understanding the cellular and molecular 
responses of B cells stimulated with antigens of varying valences lays the foundation for 






Appendix A: Effect of CpG DNA on A20 and 38C13 B cell lymphomas 
This section describes the effect of CpG DNA on A20 and 38C13 mouse B cell 
lymphomas.  
 
A20 is a mouse B cell lymphoma line expressing an IgG2a mouse BCR (H-2d, Fc
RIIB1+). A20 cells were cultured at 37°C in DMEM supplemented as described 
previously [207] and containing 15% FBS. The murine B cell lymphoma 38C13, which 
expresses surface IgM was grown as described by Woolridge et al. [295]. 38C13 has been 
extensively used to study monoclonal antibody therapy of tumors [295].  
 
Cell proliferation and apoptosis assays were carried out as described in the Materials and 
Methods in Chapter II. TLR9 mRNA was amplified as described in the same section. 
A20 and 38C13 lymphomas did not show any significant change in proliferation upon 
treatment with CpG ODN compared to the untreated or GpC treated controls (Fig. A1A). 
Similarly, the percentages of Annexin V positive, apoptotic and unstained, live cells 
remained the same at all conditions studied (Fig. A1B). This indicates that CpG ODN 
does not induce proliferation or apoptosis in these two B cell lines. TLR9 mRNA from 
the B cell lymphomas was compared with that of splenic B cells. Interestingly, both cell 
lines expressed TLR9 mRNA, with A20 expressing relatively higher levels than the 
splenic B cells (Fig. A1C). It can be speculated that detecting TLR9 mRNA might not 
effectively translate to protein expression and account for the lack of response of these 
two cell lines to CpG DNA. However, I have been unsuccessful in detecting protein 
levels of TLR9 in splenic B cells or any cell line using mAbs currently available. Taken  
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Figure A1. Effect of CpG DNA on A20 and 38C13 B cell lymphoma lines. 
(A) A20 B cell lymphomas (1 x 10^5 cells/ml) and 38C13 B cell lymphomas (1 x 10^5 
cells/ml) were treated with varying concentrations of CpG or GpC ODN for 66 hours. 
1μCi 3[H]- thymidine was added to each well for the last 18 hours of incubation, cells 
were harvested and cell associated radiation was counted using a scintillation counter. 
Data represents mean and S.D. of triplicate determinations. Shown are the representative 
results from three independent experiments. (B) A20 B cell lymphomas and 38C13 B cell 
lymphomas were incubated in the absence of or with varying concentrations GpC and 
CpG ODNs (1 μg/ml and 10 μg/ml) for 24 and 48 hrs. The cells were harvested, stained 
with Propidium Iodide (PI) and Annexin V and analyzed by flow cytometry. The 
percentages of unstained cells, indicating live cells (black bars) and percentages of 
Annexin V positive apoptotic cells (grey bars) are plotted in Figure A1B. Shown are the 
mean ± S.D. from three independent experiments. (C) mRNA was isolated from the two 
B cell lymphoma lines and splenic lymphocytes from BALB/c mice. TLR 9 mRNA was 
amplified as described in Fig. 2-3A. Tubulin mRNA was also amplified using the same 












































































together, these data indicate that A20 and 38C13 B cell lymphomas are unresponsive to 
treatment with CpG ODN and this could be a function of genotypic attributes of 























Appendix B: Convergence of BCR and TLR9 signaling pathways 
CpG ODN synergizes with BCR-induced proliferation and antibody production in mature 
B cells [170]. This section describes the attempt to characterize the cross-talk between 
BCR and TLR9 signaling pathways.   
 
Splenic B cells were treated with varying concentrations of F(ab’2) fragments of goat 
anti-mouse IgM antibody alone or in combination with 0.5 μg/ml CpG ODN. Rate of 
proliferation was analyzed as described previously. Splenic B cells were rescued from 
spontaneous apoptosis and showed marginal increase in proliferation when treated with 
increasing concentrations of anti-Ig antibody. The proliferation of splenic B cells treated 
with 0.5 μg/ml CpG alone is denoted by the grey bar. When treated with 0.5 μg/ml CpG 
ODN and varying concentrations of anti-Ig antibodies, there was a synergistic increase in 
proliferation of splenic B cells (Fig. B1). This indicates a potential convergence of the 
BCR and TLR9 signaling pathways.  
 
To follow the internalization of CpG ODN in CH27 lymphomas, immunofluorescence 
microscopy was carried out. CpG ODN was detected on the surface of the lymphomas as 
early as 10 min of stimulation (Fig. B2Ae and B2Be).These ODN are internalized and 
colocalize with LAMP-1 positive endosomal / lysosomal compartments by 30 min of 
stimulation (Fig. B2Bl). Cross-linking the surface BCR with anti-IgM antibodies 
increased the rate of CpG internalization and trafficking. At 30 min of stimulation with 
CpG ODN, only 7% of cells internalized the ODN, compared to 45% of cells whose 
surface BCR is also cross-linked. This is a significant increase in internalization of CpG  
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Figure B1. Synergistic effect of CpG DNA and BCR stimulation on proliferation of 
primary B cells.  
Splenic B cells were treated with varying concentrations of F(ab’2) fragments of goat 
anti-mouse IgM antibody alone or in combination with 0.5 μg/ml CpG ODN and 
proliferation was analyzed as described above. The proliferation with 0.5 μg/ml CpG 
ODN alone is denoted by the grey bar. Data represents mean and S.D. of triplicate 












































Figure B2. Effect of cross-linking surface BCR on internalization of CpG DNA 
CH27 lymphomas were incubated with F(ab) fragments of FITC-goat anti-mouse IgM to 
label BCR in (A) or F(ab’2) fragments of FITC-goat anti-IgM to label and cross-link the 
BCR in (B). The cells were treated with 1μM biotinylated CpG for various times at 37°C. 
The cells were then fixed, permeabilized and incubated with AlexaFluor 546- streptavidin 
and anti-mouse LAMP-1 mAb (ID4B) followed by goat anti-mouse IgG secondary 
antibody. Images were acquired in the middle of the cells using a confocal fluorescence 
microscope. Bar, 10 μm. (C) Shown is a representative image of cross-sectional analysis 
of a single cell incubated with CpG ODN for 30 min. Bar, 10 μm. (D) Shown is a 
quantitative analysis of the effect of BCR cross-linking on the internalization of CpG 
ODN. Hundred cells were counted from five random fields of each time point of the 
above experiment. The percentages of cells that had internalized CpG ODN are plotted. 
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ODN by B cells BCR and TLR9 stimulation compared to the cells where only TLR9 is 
stimulated. At 60 min there was no significant difference in percentage of cells showing 
CpG internalization (Figure B2D).  
 
Bruton’s tyrosine kinase (Btk) is a member of the Tec family of kinases. Btk is critically 
important in development of B cells and activation and division of mature B cells [296]. 
Btk has been shown to interact with the TIR domains of TLRs 4, 6, 8 and 9 [297]. It is 
also essential for activation of NF-κB and TNF-α production by TLR4 [298]. Given the 
importance of Btk in B cell survival and signaling, I attempted to characterize its 
involvement in TLR9 signaling in mature B cells.     
 
Splenic B cells were activated in the absence of or with 7 μg/ml CpG for various times or 
anti-Ig antibody for 2 mins as positive control (P) and lysed as described in Chapter II. 
Tyrosine phosphorylated proteins were immunoprecipitated from the lysates using anti-
phosphotyrosine mAb (4G10) antibody and protein G/Sepharose beads (Pharmacia, 
Piscataway, NJ). Immunoprecipitates were analyzed by SDS-PAGE and Western blotting 
with goat anti-Btk and HRP-conjugated secondary antibody. Shown is a representative 
blot. The experiment was repeated three times with similar results.  
 
Btk is a protein tyrosine kinase which is activated by phosphorylation [29]. Hence, I 
analyzed the phosphorylation of Btk as an indicator of activation. A low level of 
phosphorylated Btk (pBtk) was detected even in the untreated samples. When the cells 
were treated with CpG ODN there was a slight increase in levels of pBtk, which was also 
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seen in samples treated with the control GpC ODN (Figure B3). Cross-linking the BCR 
of splenic B cells with anti-Ig antibody induced a dramatic increase in phosphorylated 
Btk and this serves as a positive control. Taken together, the data indicates that CpG 
ODN do not lead to increase in phosphorylation of Btk in mature splenic B cells over 
levels seen with control GpC ODN. However, this does not preclude a role for Btk in the 
TLR9 signaling pathway. Binding studies show that Btk can bind to the TIR domain of 
TLR9 [297] and hence it could potentially function as an adaptor molecule in the TLR9 
pathway and not be activated by phosphorylation in B cells. 
 
Taken together, these data indicate that the BCR and TLR9 signaling pathways are 
activated synergistically and signaling through the BCR enhances internalization of CpG 
ODN. Btk has been shown to bind to the TIR domain of TLR9, but it is not 














Figure B3. Effect of CpG DNA on phosphorylation of Btk in B cells. 
Splenic B cells were treated in the absence of or with 7μg/ml of GpC and CpG ODNs for 
specified times. Cells were then lysed and immunoprecipitated with phosphotyrosine 
mAb and subjected to SDS-PAGE and Western blotting.  The blots were probed with 
anti-Btk antibody and HRP-conjugated secondary antibody. Shown is a representative 
blot of three independent experiments. P refers to a positive control where splenic B cells 
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